PRODUCTION OF RECOMBINANT POLYPEPTIDES BY BOVINE SPECIES AND TRANSGENIC METHODS

Abstract: A transgene for producing recombinant polypeptides in the milk of transgenic bovine species comprises at least one expression regulation sequence, a secretory DNA sequence encoding a secretory signal which is functional in mammary secretory cells of the bovine species and a recombinant DNA sequence encoding the recombinant polypeptides. A method for producing transgenic bovine species comprises introducing the above transgene into an embryonal target cell of a bovine species, transplanting the transgenic embryonic target cell formed thereby into a recipient bovine parent and identifying at least one female offspring which is capable of producing the recombinant polypeptide in its milk. The invention also includes transgenic bovine species capable of producing recombinant polypeptides in transgenic milk as well as the milk from such transgenic bovine species and food formulations containing one or more recombinant polypeptide. A method for producing transgenic non-human mammals having a desirable phenotype comprises first methylating a transgene followed by introduction into fertilized oocytes. The oocytes are then cultured to form preimplantation embryos. Thereafter, at least one cell is removed from each of the pre-implantation embryos and the DNA digested with a restriction endonuclease capable of cleaving the methylated transgene but incapable of cleaving the unmethylated form of the transgene.

Description: PRODUCTION OF RECOMBINANT POLYPEPTIDES BY BOVINE SPECIES AND TRANSGENIC METHODS Field of the Invention The invention relates to the production of recombinant polypeptides by transgenic bovine species andto methods for producing transgenic non-human mammals having a 5 desired phenotype. Background of the Invention There is a plethora of literature relating to the expression of heterologous genes in lower organisms such as unicellular bacteria, yeast and filamentous fungi, 10 and in higher cell types such as mammalian cells. There are also numerous reports on the production of transgenic animals, most of which relate to the production of transgenic mice. See, e.g. U.S. Pat. No. 4,736,866 (transgenic mice containing activated 15 oncogene) ; Andres, A., et al. (1987) Proc. Natl. Acad. Sci. USA 84. 1299-1303 (HA-RAS oncogene under control of whey acid protein promoter); Schoenberger, CA., et al. (1987) Experientia 43. 644 and (1988) EMBO J. 7. 169-175 (C-myc oncogene under control of whey acid 20 protein promoter); and Muller, .J., et al. (1988) Cell 54. 105-115 (C-myc oncogene under control of the mouse mammary tumor virus promoter) . Several laboratories have also reported the production of transgenic porcine species (Miller, K.F., et al. (1989) , J. Endocrin.. 120. 25 481-488 (expression of human or bovine growth hormone gene in transgenic swine); vize, P.D., et al. (1988), J. Cell Sci.. j ), 295-300 (porcine growth hormone fusion gene in transgenic pigs) ; and Ebert, K. et al. (1988) , Mol. Endocrin..2., 277-283 (MMLV-rat somatotropin fusion gene in transgenic pigs) ) , transgenic sheep (Nancarrow, et al. (1987) , Therioαenolocry.27.263 (transgenic sheep containing bovine growth hormone gene) Clark, A.J. et al. (1989) Bio/Technolo v 7. 487-482 and Simons, J., et al. (1988) Bio/Technology £, 179-183 (human factor IX and α-1 antitrypsin CONA in ovine species) , and rabbit (Hanover, S.V., et al. (1987), Deutche Tierarztliche ochenschrift. 94. 476-478 (production of transgenic rabbits by injection of uteroglobin-promoter-CAT fusion gene into fertilized rabbit oocytes) . A number of reports have also suggestedthe production of transgenic cattle (Wagner, et al. (1984) , Theriogenoloqy. 21. 29- 44) with one reporting some progress in microinjection techniques (Lohse, J.K., et al. (1985), Theriogenology. 23, 205) . However, little, if any, success has been achieved in producing transgenic cows. Scientific articleswhich clearlydemonstratethe actualproduction of a transgenic cow capable of producing a heterologous protein are presently unknown. This, despite the statements that one transgenic cow was produced in Canada which expressed human /8-interferon (Van Brunt, J. (1988) , Bio/Technology. 6_, 1149-1155) and that transient expression of human α-fetoprotein in liver and blood was obtained on one occasion (Church, R.B. (1986) , Biotechnology News Watch. 6. (15) , 4) . One reference reports that bovine papilloma virus was apparently integrated but not expressed in a transgenic cow (Roschlau et al. (1988) Arch. Tierz.. Berlin 31. 3-8). A recent article has summarized the genetic engineering of livestock. (Pursel, V.G. et al. (1989) , Science. 24_£, 1281-1288). A number of laboratories have reported tissue-specific expression of DNA encoding various proteins in the mammary gland or the production of various proteins in the milk of transgenic mice and sheep. For example, Simmons, J.P., et al. (1987) Nature 328. 530-532 report the icroinjection of a 16.2kb geno ic fragment encoding jS-lactoglobulin (BLG) including 4kb of 5' sequence, 4.9kb of the BLG transcription unit and 7.3kb of 3' flanking sequence into fertilizedmouse eggs. According to these authors, the sheep BLG was expressed in mammary tissue and produced BLG in the milk of the transgenic mice at concentrations ranging from about 3.0 to about 23 mg/ml. When, however, cDNA encoding human factor IX or human .αl-ajititrypsin was inserted into the 5' untranslated region of the BLG gene and microinjected into sheep (Simmons, J.P., et al. (1988) Bio/Technology 6 , 179-183) the production of factor IX or αl- antitrypsin was significantly reduced (25ng/ml for factor IX and lOmg/ml for αl-antitrypsin; see Clark, A.J., et al. (1989) Bio/Technology 7. 487-492). In a similar approach, a 14kb genomic clone containing the entire 7.5kb rat 3-casein together with 3.5kb of 5' and 3.Okb of 3' flanking DNA was reportedly microinjected into fertilized mouse oocytes. Lee, et al. (1988) Nucl. Acids Res. 161027-1041. Yet, in this case, the level of expression of the rat /3-transgene in the lactating mammary gland of transgenic mice was reported to be at a level of 0.01-1% of the endogenous mouse 3-casein gene. Humantissueplasminogen activator (t-PA) reportedlywas produced in transgenic mouse milk at the levels between 0.2 and about 0.4μg/ml when a cDNA encoding a human t-PA with its endogenous secretion sequence was expressed under control of a 2.6kb 5' sequence of the murine whey acid protein gene. Gordon, K., et al. (1987) Bio/Technology £5, 1183-1187. Subsequent experiments using the same or similar construction reportedly produced t-PA in different mouse lines arranging from less than 20ng of t-PA per ml of milk to about 50μg/ml. Pittius, C.W., et al. (1988) Proc. Natl. Acad. Sci. USA 8≥, 5874-5878. U.S. Patent No. 4,873,316 issued October 10, 1989, discloses the use of 9kb of 5* sequence from the bovine αSl-casein gene including the casein signal peptide and several casein codons fused to a mature t-PA sequence. The transgenic mice obtained with this construct reportedly produced about 0.2-0.5μg/ml of a t-PA fusion protein in their milk. In addition, a number of patentpublications purportedly describe the production of specific proteins in the milk of transgenic mice and sheep. See, e.g. European Patent Publication No. 0 264 166 published April 20, 1988 (hepatitis B surface antigen and t-PA genes under control of the whey acid promoter protein for mammary tissue specific expression inmice) ; PCT PublicationNo. W088/00239 published January 14, 1988 (tissue specific expression of a transgene encoding factor IX under control of a whey protein promoter in sheep) ; PCT Publication No. W088/01648 published March 10, 1988 (transgenic mouse having mammary secretory cells incorporating a recombinant expression system comprising a bovine α-lactalbumin gene fused to interleukin-2) ; European Pat. Pub. No. 0 279 582 published August 24, 1988 (tissue-specific expression of chloramphenicol acetyltransferaseunder control of rat / 8-caseinpromoter in transgenic mice) ; and PCT Pub. No. W088/10118 published December 29, 1988 (transgenic mice and sheep containing transgene encoding bovine αSl-casein promoter and signal sequence fused to t-PA) . Given the state of the transgenic art, it is apparent that a need exists for methods which enable the efficient production of transgenic mammals, especially transgenic mammals other than transgenic mice. Further, it is apparent that a need exists for methods for producing transgenic bovine species which are capable of producing recombinant polypeptides such as human milk proteins and human serum proteins in the milk of such transgenic mammals. Accordingly, it is an object herein to provide methods for detecting the transgenesis of fertilized oocytes prior to implantation. In addition, it is an object herein to provide transgenic bovine species which are capable of producing recombinant polypeptides which are maintained intracellularly or are secreted extracellularly. It is also an object herein to provide transgenic bovine species which are capable of producing recombinant polypeptides such as human milk proteins and human serum proteins in the milk of such transgenic animals. Further, it is an object herein to provide milk from a transgenic bovine species containing such recombinant polypeptides. Still further, it is an object herein to provide food formulations supplementedwithrecombinantpolypeptides from such transgenic milk such as human infant formula supplemented with human lactoferrin. Further, it is an object herein to provide transgenes which are capable of directing the production of recombinant polypeptides in the milk of transgenic bovine species. The references discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by priority based on earlier filed applications. Summary of the Invention In accordance with the above objects, the invention includes transgenes for producing recombinant polypeptides in the milk of transgenic bovine species. The production of such transgenic bovine milk containing one or more recombinant polypeptides is desirable since it provides a matrix wherein little or no purification is necessary for human consumption. The transgene comprises a secretory DNA sequence encoding a secretory signal sequencewhich is functional inmammary secretory cells of the bovine species of interest and a recombinant DNA sequence encoding the recombinant polypeptide. These sequences are operably linked to form a secretory-recombinant DNA sequence. At least one expression regulation sequence, functional in the mammary secretory cells of the bovine species, is operably linked to the secretory-recombinant DNA sequence. The transgene so constructed is capable of directing the expression of the secretory-recombinant DNA sequence in mammary secretory cells of bovine species containing the transgene. Such expression produces a form of recombinant polypeptide which is secreted from the mammary secretory cells into the milk of the transgenic bovine species. In addition, the invention includes methods for producing such transgenic bovine species. The method includes introducing the above transgene into an embryonal target cell of a bovine species, transplanting the transgenic embryonic target cell formed thereby into a recipient bovine parent and identifying at least one female offspring which is capable of producing the recombinant polypeptide in its milk. The invention also includes transgenic bovine species capable of producing recombinant polypeptides in the milk of lactating females of said species, the milk from such transgenic bovine species containing such recombinant polypeptides and food formulations containing the transgenic milk in liquid or dried form, as well as food formulations supplemented with one or more recombinantpolypeptides from suchtransgenicmilk. In addition to the foregoing, the invention includes transgenes and transgenic bovine species containing transgenes that are capable of producing a recombinant polypeptide. Such transgenes are similar to the aforementioned transgenes for milk secretion and are characterized by having an expression regulation sequence which targets the expression of the DNA encoding the recombinant polypeptide to a particular cell or tissue type, e.g. expression of human serum albumin in the liver of a transgenic bovine species. When the recombinant polypeptide is to be secreted from such targeted cells or tissues, a secretory DNA sequence encoding a secretory signal sequence functional in the particular targeted cell or tissue is operably linked to the recombinant DNA sequence encoding the recombinant polypeptide, e.g. secretion of human serum albumin from bovine liver into the bovine circulatory system. Further, the invention includes methods for producing transgenic non-human mammals having a desirable phenotype. The method comprises first causing the methylation of a transgene capable of conferring the desirable phenotype when incorporated into the cells of a transgenic non-human animal, e.g., by transforming an appropriate bacterium, such as £. coli MM 294, with a plasmid containing the transgene. The methylated transgene is then excised and introduced into fertilized oocytes of the non-human animal to permit integration into the genome. The oocytes are then cultured to form pre-implantation embryos thereby replicating the genome of each of the fertilized oocytes. Thereafter, at least one cell is removed from each of the pre-implantation embryos and treated to release the DNA contained therein. Each of the released.DNAs. are then digested with a restriction endonuclease capable of cleaving the methylated transgene but incapable of cleaving the unmethylated form of the transgene formed after integration into and replication of the genomic DNA. Thosepre-implantationembryoswhichhave integratedthe transgene contain DNA which is resistant to cleavage by the restriction endonuclease in the region containing the transgene. This resistance to digestion, which can be detected by electrophoresis of the digest after PCR amplification of the DNA and hybridization with a labelled probe for the transgene, facilitates the identification of successful transgenesis. The invention also includes a method to produce a population of transgenic offspring having the same genotype. This method utilizes a specific embodiment of the above method for detecting early transgenesis. In this method, a methylated transgene is introduced into fertilized oocytes which are cultured to pre- implantation embryos. Thereafter, each pre-implantation embryo is divided to form first and second hemi-embryos. Each of the first hemi-embryos are then analyzed for transgenesis as described above. After identifying successful transgenesis in at least one first hemi-embryo, the second untreated hemi-embryo which contains the integrated transgene, is cloned to form a multiplicity of clonal transgenic blastocysts or hemi- blastocysts, each of which have the same genotype. The transgenic embryos are thereafter transplanted into one or more recipient female parents to produce a population of transgenic non-human mammals having the same genotype. Brief Description of the Drawings The accompanying drawings, which are incorporated in and form a part of the specification, illustrate embodiments of the present invention., and, together with the description, serve to explain the principles of the invention. In the drawings: Fig. 1 depicts the DNA (Seq. ID No.: 1) and amino acid (Seq. ID No. : 2) sequence for a human lactoferrin clone derived from a human mammary cDNA library as described herein except that the sequence between nucleotides 1557-1791 and 2050-2119 corresponds to the previously published sequence (Rado et al. (1987) Blood 70. 989- 993) . Fig. 2 depicts the complete DNA (Seq. ID No. : 3) and amino acid (Seq. ID No.: 4) sequence of human lactoferrin including 5' and 3' untranslated sequence as well as the complete human lactoferrin signal sequence. Fig. 3 is a restriction map of a clone of a 5'-flanking region of bovine αSl-casein gene. Fig. 4 is a restriction map of a clone of a 3'-flanking region of bovine αSl-casein gene. Figs. 5A, 5B and 5C depict the construction of pSI3'5'CAT and pSIδ'CAT. Fig. 6 depicts pMH-1. Figs. 7A through 7F depict the construction of expression vectors containing sequences encoding human lactoferrin. Fig. 8 depicts the genome of human serum albumin, the fragments used to generate transgenic mice contained in this genomic DNA and the identification of the fragment sizes which would be obtained upon the digestion of genomic DNA from a transgenic mouse with the restriction enzymes BstE-II and Nco-I or with Nco-I and Hindi-Ill. Fig.9 depicts an alternate pathway for the construction of a transgene of the invention encoding human lactoferin. Fig. 10 depicts the construction of a plasmid pPC containing a transgene encoding Protein C. Fig. 11 depicts the DNA sequence for a hybrid intervening sequence used in a preferred embodiment of the invention. This hybrid sequence comprises a 5' portion from an intervening sequence of bovine αSl-casein and a 3' portion from an intervening sequence of an IgG intervening sequence. The juncture of the 5' and 3' portion is the Hindlll site shown. Detailed Description of the Invention The "non-human mammals'* of the invention comprise all non-human mammals capable of producing a "transgenic non-human mammal" having a "desirable phenotype". Such mammals include non-human primates, murine species, bovine species, canine species, etc. Preferred non- human animals include bovine, porcine and ovine species, most preferably bovine species. Desirable phenotypes for transgenic non-human mammals include, but are not limited to, the production of recombinant polypeptides in the milk of female transgenic non-human mammals, the production of animal models for the study of disease, the production of animals withhigher resistance to disease (e.g. diseases of the mammary gland such as mastitis) and the production of recombinant polypeptides in the blood, urine or other suitable body fluid or tissue of the animal. In the preferred embodiments, transgenic bovine species are disclosed which are capable of producing recombinant human lactoferrin, human serum albumin and human Protein C in the milk of lactating females or human serum albumin in the liver of the transgenic animal. The transgenic non-human mammals of the invention are produced by introducing a "transgene" into an embryonal target cell of the animal of choice. In one aspect of the invention, a transgene is a DNA sequence which is capable of producing a desirable phenotype when contained in the genome of cells of a transgenic non- human mammal. In specific embodiments, the transgene comprises a "recombinant DNA sequence" encoding a "recombinant polypeptide". In such cases, the transgene is capable of being expressed to produce the recombinant polypeptide. As used herein, a "recombinant polypeptide" (or the recombinant DNA sequence encoding the same) is either a "heterologous polypeptide" or a "homologous polypeptide". Heterologous polypeptides are polypeptides which are not normally produced by the transgenic animal. Examples of heterologous polypeptides include human milk proteins such as lactoferrin, lysozyme, secreted immunoglobulins, lactalbumin, bile salt-stimulated lipase, etc. , human serum proteins such as albumin, immunoglobulins, Factor VIII, Factor IX, protein C, etc. and industrial enzymes such as proteases, lipases, chitinases, and liginases from procaryotic and eucaryotic sources. The recombinant DNA sequences include genonic and cDNA sequences encoding the recombinant polypeptide. When recombinant DNA sequences encoding a heterologous polypeptide are used, the transgene may be integrated in a random manner into the genome of the species used for transgenesis. As disclosed in the Examples, transgenes encoding human lactoferrin, human serum albumin and human Protein C in conjunction with a αSl- casein secretory signal sequence under control of αSl- casein expression regulation sequences are designed to produce and secretetheseheterologouspolypeptides from the mammary gland of a lactating transgenic mammal into its milk. As used herein, a homologous polypeptide is one which is endogenous to the particular transgenic species. Examples of endogenous polypeptides from bovine species include bovine milk proteins such as αSl, αS2, β- and .c-casein, /S-lactoglobulin lactoferrin, lysozyme, cholesterol hydrolase, serum proteins such as serum albumin and proteinaceous hormones such as growth hormones. When recombinant DNA sequences encoding a homologous polypeptide are used, the transgene is preferably integrated in a randommanner into the genome of the species used for transgenesis. Such random integration results in a transgenic animal which contains not only the transgene encoding the endogenous polypeptide but also the corresponding endogenous genomic DNA sequence. Accordingly, such transgenic non- human mammals are readily characterized by an increase in the copy number of genes encoding the endogenous polypeptide. Further, the transgene will generally be located at a position which is different from the endogenous gene. When DNA encoding a homologous polypeptide is expressed, for example, in bovine species, the transgenic animal is characterized by an increase in the amount of the homologous polypeptide in either the endogenous tissue or fluid in which it is normally found and/or by its presence in a tissue and/or body fluid which either does not normally contain the homologous polypeptide or produces it at significantly, lower levels. Thus, for example, bovine cholesterol hydrolase is normally present in the colostrum for about the first 15-20 days of lactation. This naturally occurring endogenous polypeptide increases calf weight. This protein, however, is also a homologous polypeptide when, for example, its expression in mammary secretory cells is placed under the control of expression regulation sequences, such as those obtained from bovine casein genes, which facilitate the expression of the homologous polypeptide beyond the lactation period that it is normally present. Thus, according to one aspect of the invention, bovine cholesterol hydrolase expression is maintained in transgenic bovine milk by placing the expression of cholesterol hydrolase recombinant DNA (either cDNA or genomic) under the control of bovine αSl-casein expression regulation sequences. When a genomic recombinant DNA is used, it is engineered such that it has appropriate restriction sites (e.g. Clal and Sail) at the 5' and 3' end of the structural gene such that it is capable of being inserted into an appropriate transgene genomic cassette '».g. p-16 Kb, CS which is described in Example 15) . Alcernatively, a recombinant DNA encoding bovine cholesterol hydrolase derived from cDNA may be placed under control of bovine αSl-casein expressionregulation sequence by substitutingthehuman lactoferrin sequences in a plasmid such as pl6, 8HLF3 (containing a hybrid intervening sequence) or pl6, 8HLF4 (containing a homologous αSl-casein intervening sequence) . When these particular plasmids are used, the cDNA clone is engineered such that it has appropriate Clal and Sail restriction sites at the ends of the recombinant DNA. By way of further example, bovine lactoferrin is normally present in only trace amounts in cow's milk. When, however, bovine lactoferjtr-in is expressed under control of other regulatory sequences, for example, obtained from an αSl-casein gene, higher amounts of lactoferrin in the milk of transgenic bovine species are obtained. In another example, a transgene comprising DNA encoding homologous bovine growth hormone is incorporated into the bovine genome to confer superior growth characteristics to the transgenic animal. In other instances, homologous polypeptides include, for example, a polypeptide which normally is maintained intracellularly in a particular species but which is secreted into the milk or other extracellular compartment of the transgenic species, such as the circulatory system. Each of the heterologous or homologous polypeptides are characterized by specific amino acid and nucleic acid sequences. It is to be understood, however, that such sequences include naturally occurring allelic variations thereof and variants produced by recombinant methods wherein such nucleic acid andpolypeptide sequences have been modified by the substitution, insertion and/or deletion of one or more nucleotides in such nucleic acids to cause the substitution, insertion or deletion of one ore more amino acid residues in the recombinant polypeptide. When expression of the DNA of the transgene is necessary to generate a desired phenotype, e.g. to produce a recombinant polypeptide, the transgene typically includes at least a 5' and preferably additional 3' "expression regulation sequences" each operably linked to a recombinant or secretory-recombinant DNA as defined hereinafter. Such expression regulation sequences in addition to controlling transcription also contribute to RNA stability and processing, at least to the extent they are also transcribed. Such expression regulation sequences are chosen to produce tissue-specific or cell type-specific expression of the recombinant or secretory-recombinant DNA. Once a tissue or cell type is chosen for expression, 5' and optional 3' expression regulation sequences are chosen. Generally, such expression regulation sequences are derived from genes that are expressed primarily in the tissue or cell type chosen. Preferably, the genes from which these expressionregulation sequences are obtained are expressed substantially only in the tissue or cell type chosen, although secondary expression in other tissue and/or cell types is acceptable if expression of the recombinant DNA in the transgene in such tissue or cell type is not detrimental to the transgenic animal. Particularly preferred expression regulation sequences are those endogenous to the species of animal to be manipulated. However, expression regulation sequences from other species such as those from human genes may also be used. In some instances, the expression regulation sequences and the recombinant DNA sequences (either genomic or CDNA) are from the same species, e.g., each from bovine species or from a human source. In such cases, the expression regulation sequence and the recombinant DNA sequence are homologous to each other. Alteratively, the expression regulation sequences and recombinant DNA sequences (either cDNA or genomic) are obtained from different species, e.g., an expression regulation sequence from bovine species and a recombinant DNA sequence from a human source) . In such cases, the expression regulation and recombinant DNA sequence are heterologous to each other. The following defines expression regulation sequences from endogenous genes. Such definitions are also applicable to expression regulation sequences from non-endogenous, heterologous genes. I Inn,l<general, the 5' expression regulation sequence includes the transcribed portion of the endogenous gene upstream from the translation initiation sequence (the 5' untranslated region or 5' UTR) and those flanking sequences upstreamtherefromwhich comprise a functional promoter. As used herein, a "functional promoter" includes those necessary untranscribed DNA sequences which direct the binding of RNA polymerase to the endogenous gene to promote transcription. Such sequences typically comprise a TATA sequence or box located generally about 25 to 30 nucleotides from the transcription initiation site. The TATA box is also sometimes referred to the proximal signal. In many instances, the promoter further comprises one or more distal signals located upstream from the proximal signal (TATA box) which are necessary to initiate transcription. Such promoter sequences are generally contained within the first 100 to 200 nucleotides locatedupstream fromthetranscription initiation site, but may extend up to 500 to 600 nucleotides from the transcription initiation site. Such sequences are either readily apparent to those skilled in the art or readily identifiable by standardmethods. Such promoter sequences alone or in combination with the 5' untranslated region are referred to herein as "proximal 5' expression regulation sequences". In addition to such proximal 5' expression regulation sequences, it is preferred that additional 5' flanking sequences (referred to herein as "distal 5* expression regulation sequences'*) also be included in the transgene. Such distal 5' expression regulation sequences are believed to contain one or more enhancer and/or other sequences which facilitate expression of the endogenous gene and as a consequence facilitate the expression of the recombinant or secretory-recombinant DNA sequence operably linked to the distal and proximal 5' expression regulation sequences. The amount of distal 5' expression regulation sequence depends upon the endogenous gene fromwhich the expression regulation sequences are derived. In general, however, such sequences comprise 5• flanking regions of approximately lkb, more preferably 16kb and most preferably about 30kb of 5' flanking sequence. The determination of the optimal amount of distal 5' expression regulation sequence used from any particular endogenous gene is readily determined by varying the amount of distal 5' expression regulation sequence to obtain maximal expression. In general, the distal 5' expression regulation sequence will not be so large as to extend into an adjacent gene and will not include DNA sequences which adversely effect the level of transgene expression. In addition, it is preferred that 3• expression regulation sequences also be included to supplement tissue or cell-type specific expression. Such 3' expression regulation sequences include 3' proximal and 3 • distal expression regulation sequences from an appropriate endogenous gene. The 3' proximal expression regulation sequences include transcribed but untranslated DNA positioned downstream from the translation stop signal in the recombinant DNA sequence (also referred to as the 3• untranslated region or 3• UTR) . Such sequences generally terminate at a polyadenylation sequence (either from the endogenous gene or from other sources such as SV40) and sequences that may affect RNA stability. Generally, 3' UTR's comprise about 100 to 500 nucleotides downstream from the translation stop signal in the gene from which the 3' regulation sequence is derived. Distal 3' expression regulation sequences include flanking DNA sequences downstream from the proximal 3• expression regulation sequence. Some of these distal sequences are transcribed, bu . do not form part of the mRNA while other sequences in this distal 3* expression regulation sequence are not transcribed at all. Such distal 3' expression regulation sequences are believed to contain enhancer and/or other sequences which enhance expression. Such sequences are believed to be necessary for efficient polydenylation and contain transcription termination sequences Preferably, such sequences comprise about 2kb, more preferably 8kb and most preferably about 15kb of 3' flanking sequence. Although the use of both 5' and 3' expression regulation sequences are preferred, in some embodiments of the invention, endogenous 3• regulation sequences are not used. In such cases, the 3' proximal expression regulation sequences normally associated with the genomic DNA encoded by the recombinant DNA sequence are used to direct polyadenylation. In addition, distal 3' regulation sequences from the genomic DNA encoding the recombinant polypeptide may also be employed preferably in the same amounts as set forth for endogenous 3' expression regulation sequences. In such cases, it is to be understood that the recombinant polypeptide encoded by thetransgene may comprise either genomic DNA or a double stranded DNA derived from cDNA. As with the 5* expression regulation sequences, the optimal amount of 3' expression regulation sequence may be readily determined by varying the amount of 3' flanking sequence to obtain maximal expression of the recombinant polypeptide. In general, the distal 3' regulation sequence, be it from an endogenous gene or a heterologous gene, will not extend into the adjacent gene from which is derived and will exclude any sequences which adversely effect the level of transgene expression. Examples of expressionregulation sequences areprovided in Table I. TABLE 1 Expression Regulation Tissue Animal Sequence Specificity Species 16kb of bovine oSl Mammary bovine casein 5' to structural secretory gene and 8kb 3' to cells structural gene «15kb 5' to albumin Liver murine gene «15kb 5' to α-actin Muscle murine gene «15kb upstream of Spermatids murine protamine gene In addition to the 5' and 3' expression regulation sequences and the recombinant DNA (either genomic or derived from cDNA) the transgenes of the invention preferably also comprise a "recombinant intervening sequence" which interrupts the transcribed but untranslated 5* region of the transgene. Such intervening sequences can be derived, for example, from bovine αSl-casein and from human lactoferrin. Such sequences as used herein are "homologous recombinant intervening sequences" in that the 5' and 3' RNA splice signals in such recombinant intervening sequences are those normally found in an intervening sequence from an endogenous or heterologous gene. Recombinant intervening sequences may, however, also comprise a "hybrid intervening sequence". Such hybrid intervening sequences comprise a 5* RNA splice signal and 3• RNA splice signal from intervening sequences from different sources. In some aspects of the invention, such hybrid intervening sequences comprise at least one "permissive RNA splice sequence". As used herein, a permissive RNA splice signal is an RNA splice signal sequence, preferably a 3' RNA splice signal, from an intron contained within a repertoire of germ line DNA segments which undergo rearrangement during cell differentiation. Examples of such gene repertoires include the immunoglobulin super gene family, including the immunoglobulins and T-cell antigen receptors as well as the repertoire of the major histocompatibility complex (MHC) genes and others. Particularly preferred permissive splice sequences are those obtained from the immunoglobulin repertoire, preferably of the IgG class, and more preferably those 3' splice signal sequences associated with the J-C segment rearrangement of the Ig heavy and light chain, most preferably the heavy chain. A particularly preferred permissive splice sequence comprises that portion of the sequence as shown downstream of the Hindlll site in Fig. 11. A particularly preferred hybrid intervening sequence comprises the entire sequence shown in Fig. 11 which includes a 5' portion of an intervening sequence from bovine αSl-casein and a 3' sequence portion of an IgG heavy chain intervening sequence. Such hybrid intervening sequences containing permissive RNA splice signals are preferably used when the recombinant DNA corresponds to a cDNA sequence. As indicated in the Examples, when 16kb of 5' expression regulation sequence from the αSl-casein gene was used in conjunctionwith anαSl-casein-IgGhybrid intervening sequence to express human lactoferrin cDNA operably linked to the αSl-casein secretory signal sequence a transgenic mouse was obtained which produced approximately 1330 μg/ml of hLF in the transgenic milk. This amount of recombinant polypeptide far exceeds the previously reported amounts for production of various protein in transgenic mouse milk of generally less than 10 μg/ml and in one case approximately 50 μg/ml. It also exceeds the maximum of 8μg/ml of hLF produced herein when the same transgene was used that contained a homologous bovine intervening sequence rather than the hybrid intervening sequence. However, such hybrid intervening sequences are not limited to transgenes utilizing cDNA sequence. Rather, hybrid intervening sequences are also useful when the recombinant polypeptide is encoded by a genomic sequence. Based on the results obtained with the cDNA recombinant DNA and the general expectation that genomic DNA sequences express at higher levels than sequences derived from cDNA, it is expected that such hybrid intervening sequences used in conjunction with genomic recombinant DNA will further enhance expression levels above that which would otherwise be obtained with genomic sequence alone. Based on the foregoing, it is apparent that preferred transgenes include large amounts of 5' and 3' expression regulation sequences. Further, the recombinant DNA is preferably derived from genomic clones which may be tens to hundreds of kilobases in length. Based on the present technology for cloning andmanipulating DNA, the construction and icroinjection of transgenes is practically limited to linearized DNA having a length not greater than about 50kb. However, the transgenes of the invention, especially those having a length greater than about 50kb, may be readily generated by introducing two or more overlapping fragments of the desired transgene into an embryonal target cell. When so introduced, the overlapping fragments undergo homologous recombination which results in integration of the fully reconstituted transgene in the genome of the target cell. In general, it is preferred that such overlapping transgene fragments have 100% homology in those regions which overlap. However, lower sequence homology may be tolerated provided efficient homologous recombination occurs. If non-homology does exist between the homologous sequence portions, it is preferred thatthe non-homology not be spread throughout the homologous sequence portion but rather be located in discrete areas. Although as few as 14 base pairs at 100% homology are sufficient for homologous recombination in mammalian cells (Rubnitz, J. and Subramani, S. (1984) Mol. Cell. Biol. 4. 2253-2258), longer homologous sequence portions are preferred, e.g. 500bp, more preferably lOOObp, next most preferably 2000bp and most preferably greater than 2000bp for each homologous sequence portion. As indicated in the examples, three overlapping fragments of the human serum albumin gene were microinjected into the pronuclei of mouse zygotes in approximately equal molar portions. These fragments successfully recombined and integrated into the mouse genome as confirmed by analysis of the integrated DNA by Southern blotting procedures and by detection of RNA transcript and human serum albumin in the serum of the transgenic mouse. Although the transgene so generated has a unit length of 38kb, there is no known practical limit to the size of the transgene which may be formed using larger and/or greater numbers of overlapping transgene fragments. In particular, it is expected that transgenes may be formed by this approach having lengths between about 50 to lOOOkb and more preferably between 50 and 500kb. Further, the use of homologous recombination of overlapping fragments is expected to be fruitful in the generation of larger transgenic animals, such as transgenic bovine species, containing transgenes incorporating recombinant DNA comprising genomic DNA which otherwise could not be incorporated into a pronucleus to form a transgenic animal. Such genomic transgenes are expected to produce higher expression levels in transgenic cows as compared to that rtiich is produced by transgenes encoding recombinant cDNA. When, the ultimate object is to secrete a recombinant polypeptide, a "secretory DNA sequence" encoding a functional secretion signal peptide is also operably linked within the transgene to direct secretion of the recombinant polypeptide from one or more cell types within the transgenic animal. Secretory DNA sequences in general are derived from genes encoding secreted proteins of the same species of the transgenic animal. Such secretory DNA sequences are preferably derived from genes encoding polypeptides secreted from the cell type targeted for tissue-specific expression, e.g. secreted milk proteins for expression in and secretion from mammary secretory cells. Secretory DNA sequences, however, are not limited to such sequences. Secretory DNA sequences from proteins secreted from other cell types within the species of transgenic animal may also be used, e.g., the native signal sequence of a homologous gene encoding a protein secreted other than in the mammary glands. In addition, "heterologous secretory DNA sequences" which encode signal secretion peptides from species other than the transgenic animals y also be used e.g., human t-PA, human serum albumin human lactoferrin and human lactalbumin and secretion signals from microbial genes encoding secreted polypeptides such as from yeast, filamentous fungi, and bacteria. In general, a secretory DNA sequence may be defined functionally as any DNA sequence which when operably linked to a recombinant DNA sequence encodes a signal peptide which is capable of causing the secretion of the recombinant polypeptide. In one of the preferred embodiments, a secretory DNA sequence encodinga secretorysignal sequence functional in the mammary secretory cells of bovine species is used to auie secretion of recombinant polypeptide_ from bovine mammary secretory cells. The secretory DNA sequence is operably linked to the recombinant DNA sequence. Examples of such secretory DNA sequences include DNA sequences encoding signal secretion sequences for bovine αtSl-casein, murine lactoferrin and human transferrin. The preferred secretory DNA sequence is that encoding the secretory sequence of αSl-casein from bovine species. The use of this secretory DNA sequence is described in more detail in the Examples. "Operably linked" in the context of linking a secretory DNA sequence to a recombinant DNA sequence means that the secretory DNA sequence (comprising codons encoding the secretory signal peptide sequence) is covalently coupled to the recombinant DNA sequence so that the resultant secretory-recombinant DNA sequence encodes 5' to 3• for the secretory signal sequence and recombinant polypeptide. Accordingly, the reading frame for the secretory sequence and the recombinant DNA sequencemust be covalently combined such that an open reading frame exists from the 5• end of the mRNA sequence formed after transcription and processing of the primary RNA transcript. This open reading frame in the RNA contains a 5' sequence portion encoding the secretory signal peptide and a 3' sequence portion encoding the recombinant polypeptide. When so constructed, the recombinant polypeptide produced upon expression of the secretory-recombinant DNA sequence is of a form which is capable of being secreted from targeted cells which express the DNA sequence. The signal peptide generally is removed in vivo during secretion to produce an extracellular form of the recombinant polypeptide. In the preferred embodiments of the invention, a secretory-recombinant DNA sequence is expressed predominantly in the mammary secretory cells of transgenic bovine species.., ,Such tissue-specific expression is obtained by operably linking mammary specific expression regulation DNA sequences to the above secretory-recombinant DNA sequence. Such mammary specific regulation sequences include the aforementioned regulation sequences contained in various bovine genes preferentially expressed in the mammary secretory cells of the species. Such mammary specific genes include αSl-casein; αS2-casein; 3-casein; K-casein; α-lactalbumin; and /3-lactoglobulin. Preferred expression regulation sequences are derived from αSl- casein as described more in detail in the Examples. In general, the transgenes of the invention that are designed to secrete the recombinant polypeptide into transgenic bovine milk are capable of causing such secretion at levels significantly higher than that previously reported for transgenic mice and sheep. When the recombinant polypeptide is encoded by a recombinant DNA corresponding to, or derived from, cDNA, the molar concentration of the recombinant polypeptide is preferably greater than about 1.0 μM, more preferably greater than about 100 μM, and most preferably greater than 100 μM. When viewed from the perspective of the level of recombinant polypeptide present in the transgenic milk, the amount of recombinant polypeptide is preferably greater than 50 μg/ml, more preferably greater than about 500 μg/ml and most preferably greater than about 1000 μg/ml (lmg/ml) . When the transgene of the invention encodes a recombinant polypeptide that is encoded by recombinant DNA derived from or corresponding to genomic DNA (or comprised substantially of such genomic sequences, e.g. greater than about 50%, more preferably greater than about 75%, most preferably greater than 90% of the codons encoding the recombinant polypeptide are from genomic sequences) , themolarconcentrations andprotein levels in bovine transgenic milk are the same as for cDNA or higher. In general, the molar concentration of the recombinant polypeptide in such transgenic milk is preferably greater than about 50 μM, more preferably greater than about 150 μM, most preferably greater than about 500 μM. When viewed from the level of protein in the transgenic milk, the levels are preferably greater than about 10 mg/ml, more preferably greater than about 2.5 mg/ml, most preferably greater than 5 mg/ml. The foregoing molar concentration and protein levels in bovine transgenic milk will vary depending upon the molecular weight of the particular recombinant polypeptide. A particular advantage of producing a recombinant polypeptide in bovine transgenic milk is that relatively large molecular weight polypeptides may be so produced which are otherwise difficult to produce in large quantities in other systems such as prokaryotic expression systems. Although any recombinant polypeptide may be produced in bovine transgenic milk according to the invention, it is generally preferred that such recombinant polypeptides have a molecular weight greater than about 10,000 Daltons. However, other recombinant polypeptides having molecular weights of greater than 15,000, greater than 20,000 and greater than 60,000 Daltons may also be expressed in transgenic bovine milk. For example, human lysozyme having a molecular weight of 17,000 Daltons and lactoferrin having a molecular weight of 79,000 Daltons may be readily produced in the transgenic milk of bovine species according to the disclosure of the invention. Thus, the recombinant polypeptides of the inventionhave a wide range of molecular weights. As a consequence, the foregoing preferred molar concentrations of recombinant polypeptides are adjusted when higher molecular weight recombinant polypeptides are produced. Such adjustment is made by converting the molar concentration to the amount of protein produced and adjusting the molar concentrations so that the recombinant protein level is within the following preferred concentrations. Most of the previous reports relating to the production of polypeptides in transgenic milk involve transgenic mice. The mouse, however, normally produces between 55 to 80 milligrams of protein per ml of milk. A cow, on the other hand, normally produces between 30 to 34 milligrams of protein per ml. Since exceptionally high levels of recombinant polypeptide production may adversely affect the production of endogenous milk protein and/or have adverse effects upon the mammary secretory gland, it is preferred that the recombinant polypeptide concentration be between about 3 and 50% of the normal bovine milk protein concentration (i.e. , between about 1 and 17 milligrams of recombinant polypeptide per ml of transgenic milk) , more preferably between 10 to 20% (i.e. , between 3 to about 7 milligrams per ml) and most preferably between 10 and 15% (i.e.., between about 3 and 5 milligrams per ml) of the normal amount of protein produced in bovine milk. Such preferred ranges also provide a preferred maximum limit to the aforementioned levels of protein produced in transgenic bovine milk. The above described linking of various DNA sequences to form the transgene of the invention are performed by standard methods known to those skilled in the art or as described herein. Once the transgene or overlapping homologous fragments encoding the transgene are constructed as described they are used to make transgenic non-human animals. Methods of introducing transgenes or overlapping transgene fragments into embryonal target cells include microinjection of the transgene into the pronuclei of fertilized oocytes or nuclei of ES cells of the non- human animal. Such methods for murine species are well known to those skilled in the art. Alternatively, the transgene may be introduced into an animal by infection of zygotes with a retrovirus containing the transgene (Jaenisch, R. (1976) , Proc. Natl. Acad. Sci. USA. 73. 1260-1264) . The preferred method is microinjection of the fertilized oocyte. In this preferred embodiment, the fertilized oocytes are first microinjected by standard techniques. They are thereafter cultured in vitro until a "pre-implantation embryo" is obtained. Such pre-implantation embryos preferably contain approximately 16 to 150 cells. The 16 to 32 cell stage of an embryo is commonly referred to as a morula. Those pre-implantation embryos containing more than 32 cells are commonly referred to as blastocysts. They are generally characterized as demonstrating the development of a blastocoel cavity typically at the 64 cell stage. Methods for culturing fertilized oocytes to the pre- implantation stage include those described by Gordon, et al. (1984), Methods in Enzvmology.101, 414; Hogan, et al. (1986) in Manipulating the Mouse Embrvo. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (for the mouse embryo) ; and Hammer, et al. (1985) , Nature. 315. 680 (for rabbit and porcine embryos) Gandolfi et al. (1987) J. Reprod. Fert. 81. 23-28; Rexroad et al. (1988) J. Anim. Sci. 66. 947-953 (for ovine embryos) and Eyestone, W.H. et al. (1989) , J. Reprod. Fert.. 85. 715-720; Ca ous., et al. (1984), 3^. Reprod. Fert.. 72, 779-785; and Hey an, Y. , et al. (1987), Theriogenology. 22, 5968 (for bovine embryos). Such pre-implantation embryos are thereafter transferred to an appropriate female by standard methods to permit the birth of a transgenic or chimeric animal depending upon the stage of development when the transgene is introduced. As is well known, mosaic animals can be bred to form true germline transgenic animals. Since the frequency of transgene incorporation is often low, the detection of transgene integration in the pre- implantation embryo is highly desirable. In one aspect of the invention methods are provided for identifying embryos wherein transgenesis has occurred and which permit implantation of transgenic embryos to form transgenic animals. In this method, one or more cells are removed from the pre-implantation embryo. When equal division is used, the embryo is preferably not cultivated past the morula stage (32 cells) . Division of the pre-implantation embryo (reviewed by Williams et al. (1986) Theriogenologv 22, 521-531) results in two "hemi-embryos" (hemi-morula or hemi-blastocyst) one of which is capable of subsequent development after implantation into the appropriate female to develop in utero to term. Although equal division of the pre- implantation embryo is preferred, it is to be understood that such an embryo may be unequally divided either intentionally or unintentionally into two hemi-embryos which are not necessarily of equal cell number. Essentially, all that is required is that one of the embryos which is not analyzed as hereinafter described be of sufficient cell number to develop to full term in utero. In a specific embodiment, the hemi-embryo which is not analyzed as described herein, if shown to be transgenic, is used to generate a clonal population of transgenic non-human animals. One of each of the hemi-embryos formed by division of pre-implantation embryos is analyzedto determine if the transgene has been integrated into the genome of the organism. Each of the other hemi-embryos is maintained for subsequent implantation into a recipient female of the species. A preferred method for detecting transgenesis at this early stage in the embryo's development uses these hemi-embryos in connection with a unique property of the restriction endonuclease Dpn X. This enzyme recognizes the sequence GATC in double- stranded DNA but only when the adenine in each strand within this sequence is methylated at N-6. When using this preferred method, the transgene containing the sequence GATC is methylated prior to microinjection either by transferring the transgene on an appropriate plasmid through a DAM + strain of microorganisms such as E. coli MM294 or by directly methylating the transgene with dam methylase. The methylated transgene (preferably without any exogenous sequences such as plasmid vector) is then microinjected into fertilized oocytes (approximately 10 to 500 copies per pronucleus, more preferably 50 to 100 copies per pronucleus) . The fertilized oocytes so obtained are cultured in vitro to the pre-implantation stage. During this early growth and cell division phase, the genomic DNA is replicated. Accordingly, those copies of the methylated transgene integrated into the genome of the fertilized oocyte are unmethylated after replication whereas any non- integrated transgenes which may still exist after replication will remain methylated. (Lacks, S., et al. (1977), J. Mol. Biol.. 114. 153.) This differential methylation pattern for integrated versus non-integrated transgenepermits the identification ofwhich fertilized oocytes have integrated the transgene into the genome. The identification of the pre-implantation embryos containing the integrated transgene is achieved by analyzing the DNA from each of the hemi-embryos. Such DNA is typically obtained by lysing the hemi-embryo and analyzing the thus released DNA after treatment as described by Ninomiy, T. et al. (1989) molecular Reproduction and Development 1, 242-248. Each of the DNA samples is treated with Dpn I. Thereafter, a polymerase chain reaction (Saiki, et al. (1985), Science. 230. 1350-1354) is preformed to amplify all or part of the transgene. When the entire transgene is amplified, two extension primers each complimentary to opposite strands at opposing ends of the transgene are used for amplification. When, however, less than the entire transgene is amplified, such extension primers are chosen such that the amplified gene product spans the Dpn I site in the transgene. If Don I cleavage has not occurred, PCR amplification results in amplified sequences having a predetermined size whereas primer extension for those transgenes which have been cleaved will not result in exponential amplification. Generally, the Dpn I/PCR amplified DNA from the hemi- embryo is subjected to electrophoresis followed by hybridization with labeled probe complimentary to the region of the transgene between the two extension primers. This facilities the determination of the size of the amplified DNA sequences, if any, and provides an indication of whether the transgene has been integrated into the pre-implantation embryo from which the hemi- embryo was obtained (now called a "transgenic hemi- embryo") . If it has, the remaining untreated transgenic hemi-embryo is transplanted into a recipient parent. After in utero development, the transgenic non-human animal having the desired phenotype conferred by the integrated transgene is identified by an appropriate method in utero or after birth. Of course, other restriction endonucleases capable of cleaving a methylated DNA sequence but incapable of cleaving the un ethylated form of a recognition sequence may be used in the aforementioned method. The above described method using Dpn I requires that the sequence GATC be present in the transgene of interest. In those cases when such a sequence is not present, it may be readily introduced into the transgene by site directed mutagenesis (Kunkel, T.A. (1985) , Proc. Natl. Acad. Sci.. 82. 488) or cassette mutagenesis (Wells, J.A., et al. (1985), Ggne, 3_4_, 315) provided such mutagenesis does not change the amino acid sequence encoded by the transgene (or causes an inconsequential change in amino acid sequence) and that any codons so generated are functional in the transgenic non-human animal of interest. The above described methods for the detection of transgenesis in pre-implantation embryos provide economical and time saving method for generating transgenic non-human animals since they significantly decrease the number of pregnancies required to produce a transgenic animal and substantially increase the likelihood that an implanted embryo will produce a transgenic non-human animal. Such methods are especially important for those animals for which very low or non-existent frequencies of transgenesis have been obtained, e.g. bovine species. In an alternate embodiment, the above described method for detecting transgenesis in pre-implantation embryos is combined with embryonic cloning steps to generate a clonal population of transgenic embryos which may thereafter be implanted into recipient females to produce a clonal population of transgenic non-human animals also having the same genotype. In this regard, it is to be understood that transgenic embryos and/or non-human transgenic animals having the same "genotype" means that the genomic DNA is substantially identical between the individuals of the embryo and/or transgenic animal population. It is to be understood, however, that during mitosis various somatic mutations may occur which may produce variations in the genotype of one or more cells and/or animals. Thus, a population having the same genotype may demonstrate individual or subpopulation variations. After a hemi-embryo is identified as a transgenic hemi- embryo, it is cloned. Such embryo cloning may be performed by several different approaches. In one cloning method, the transgenic hemi-embryo is cultured in the same or in a similar media as used to culture individual oocytes to the pre-implantation stage. The "transgenic embryo" so formed (preferably a transgenic morula) is then divided into "transgenic hemi-embryos" which can then be implanted into a recipient female to form a clonal population of two transgenic non-human animals. Alternatively, thetwo transgenichemi-embryos obtainedmay be again cultivated to the pre-implantation stage, divided, and recultivated to the transgenic embryo stage. This procedure is repeated until the desired number of clonal transgenic embryos having the same genotype are obtained. Such transgenic embryos may then be implanted into recipient females to produce a clonal population of transgenic non-hum_:n animals. In a preferred cloning method, the transgenic embryo is cloned by nuclear transfer according to the techniques of Prather et al. (1988) Biol. Reprod. 37. 59-86; Roble et al. (1987) J. Anim. Sci. 64. 642-664. According to this method, nuclei of the transgenic embryo are transplanted into enucleated oocytes, each of which is thereafter cultured to the blastocyst stage. At this point, the transgenic embryos may be resubjected to another round of cloning by nuclear transplantation or may be transferred to a recipient parent for production of transgenic offspring having the same genotype. In addition to the foregoing methods for detecting early transgenesis, other methods may be used to detect transgenesis. Such methods include in utero and post partum analysis of tissue. In utero analysis is performed by several techniques. In one, transvaginal puncture of the amniotic cavity is performed under echoscopic guidance (Bowgso et al. (1975) Bet. Res. 96. 124-127; Ru sey et al. (1974) J. Anim. Sci. 39. 386-391) . This involves recovering about 15 to 20 milliliters of amniotic fluid between about day 35 and day 100 of gestation. This volume of amniotic fluid contains about 1000 to 12,000 cells per ml originating from the urogenital tract, the skin and possibly the lungs of the developing embryo. Most of these cells are dead. Such cells, however, contain genomic DNA which is subjected to PCR analysis for the transgene as an indicationof a successfultransgenesis. Alternatively, fetal cells may be recovered by chorion puncture. This method also may be performed transvaginally and under echoscopic guidance. In this method, a needle is used to puncture the recipient animal's placenta, particularlytheplacentonal structures, which are fixed against the vaginal wall. Such sampling may be performed around day 60 of gestation in bovine species. Chorion cells, if necessary, are separated frommaternal tissue and subjected to PCR analysis for the transgene as an indication of successful transgenesis. Transgenesis may also be detected after birth. In such cases, transgene integration can be detected by taking an appropriate tissue biopsy such as from the ear or tail of the putative transgenic animal. About one to two centimeters of tail or about five to ten square millimeters of ear are obtained followed by southern blotting with a probe for the transgene according to the method of Hogan et al. (1986) Manipulating the Mouse Embryo. Cold Spring Harbor Laboratory. in those embodiments where a recombinant polypeptide is expressed and secreted into the milk of transgenic bovine species, the transgenic milk so obtained may be either used as is or further treated to purify the recombinant polypeptide. This depends, in part, on the recombinantpolypeptide contained inthe transgenicmilk and the ultimate use for that protein. Thus, when the recombinant polypeptide is secreted intotransgenicmilk to increase the nutritional value of the bovine milk, no further purification is generally necessary. An example of such a situation involves one of the preferred embodiments wherein human lactoferrin is produced in the milk of bovine species as a supplement to control intestinal tract infections in newborn human infants and to improve iron absorption. In other situations, a partial purification may be desired to isolate a particular recombinant polypeptide for its nutritional value. Thus, for example, human lactoferrin produced in transgenic bovine milk may be partially purified by acidifying the milk to about pH 4-5 to precipitate caseins. The soluble fraction (the whey) contains the human lactoferrin which is partially purified. The recombinant polypeptide contained in bovine transgenic milk may also be used in food formulations. A particularly useful food formulation comprises an infant formula containing one or more recombinant polypeptides from transgenic bovine milk which have either nutritional or other beneficial value. For example, an infant formula containing human lactoferrin from transgenic bovine milk made according to the present inventionprovides a bacteriostatic effectwhich aids in controlling diarrhea in newborn. Similarly, recombinant polypeptides such as human casein and human lysozyme may also be generated in transgenic bovine milk to provide nutritional value. Table 2 sets forth the constituents of a typical infant formula. As indicated therein, the protein content varies between about 1.8 and 4.5 grams of protein per 100 kilocalories of formula. Thus, the total protein including recombinant polypeptide should lie between the values at least based on regulatory requirements in the United States from which the formulation in Table 2 is based. The amount of total protein including recombinant polypeptide, of course, may vary from the-foregoing depending upon the local regulations where the particular formula is intended to be used. IABLE_2 Nutrient Hinimum* Maximum* Protein (gm)' 1.8 k 4.5 Fat: • Stated per 100 kilocalories. "The source of protein shall be at least nutritionally equivalent to casein. "Retinol equivalents. 'Required to be included in this amount only in formulas uhich are not milk-based. 'Calcium to phosphorus ratio must be no less than 1.1 nor more than 2.0. 'includes recombinant protein according to the invention or recombinant proteins and other proteins. In addition to infant formulas, other food formulations may also be supplemented with recombinant polypeptides from transgenic bovine milk. For example, such recombinant polypeptides may be used to supplement common diet formulations. When the recombinant polypeptide is intended to be used pharmaceutically, purification methods consistent with such an application are called for. Such purification methods will depend on the particular recombinant polypeptide to be purified and are generally known to those skilled in the art. Such methods typically include a partial purification by casein fractionation followed by chromotography of the appropriate fraction containing the recombinant polypeptide. Such chromotography includes affinity chromotography, ion exchange chromotography, gel filtration and HPLC. In a specific embodiment of the invention, transgenes are provided for producing human lactoferrin in the milk of transgenic bovine species. Human lactoferrin (HLF) is a single chain glycoprotein which binds two ferric ions. Secreted by exocrine glands (Mason et al. (1978) J. Clin. Path. 31. 316-327; Tenovuo et al. (1986) Infect. Immun. 51, 49-53) and polymorphonuclear neutrophil granulocytes (Mason et al. (1969) J. Exp. Med. 130,. 643-658) , this protein functions as part of a host non-specific defense system by inhibiting the growth of a diverse spectrum of bacteria. HLF exhibits a bacteriostatic effect by chelation of the available iron in the media, making this essential metal inaccessible to the invading microorganisms (Bullen et al. (1972) Br. Med. J.1, 69-75; Griffiths et al. (1977) Infect. Immun. 15, 396-401; Spik et al. (1978) Immunology j£, 663-671; Stuart et al. (1984) Int. J. Biochem. l≤., 1043-1947) . This effect is blocked if the protein is saturated with ferric ions. Several studies suggest that HLF displays a direct bacteriocidal effect on certain microorganisms (Arnold et al. (1980) Infect. Immun. 28. 893-898; Arnold et al. (1977) Science 197. 263-265; Arnold et al. (1981) Infect. Immun. 32. 655-660; Arnold et al. (1982) Infect. Immun. 35. 792-797; Bortner et al. (1986) Infect. Immun. 51. 373-377) . The bacteriocidal effect is also inhibited by iron saturation of the protein. No mechanism for the bactericidal effect of HLF has beenpostulated, although it has been demonstrated that it can damage the outer membrane and alter outer membrane permeability in gram- negative bacteria (Ellison et al. (1988) Infect. Immun. 6, 2774-2781) . Lactoferrin is the major iron binding-protei tin human milk (present at a concentration of about 1.5-1.7 mg/ml) and may play a role in the absorption of iron by the small intestine. All of the iron present in breast milk is thought to be bound to hLF and is taken up at very high efficiencies compared to formula (Hide, D.W., et al. (1981) , Arch. Pis. Child.. 56. 172) . It has been postulated that the high uptake of the hLF bound iron is due to a receptor in the jejunum and data has been presented suggesting existence of receptors in Rhesus monkeys (Cox, et al. (1979), BBA, 588. 120; Davidson, L.A., et al. (1985), Fed. Proc.. 18 f 901). There is also evidence for specific lactoferrin receptors on mucosal cells of the small intestine of human adults (Cox, et al. (1979) Biochem. Bioohys. Acta. 588. 120- 128) . Free iron levels have been implicated in the control of the intestinal flora (Mevissen-Verhage, et al. (1985) , Eur. J. Clin. Microbiol.. 4_, 14) . Breast fed infants, compared with infants fed cow's milk, with and without added iron, were shown to have substantially reduced coliform and, elevated bifidobacteria and clostridia counts in fecal samples. In in vitro studies, human milk has been shown to have a specific inhibitory effect on EL. coli (Brock, et al. (1983) , Infect, and Immunit.. 40. 453) . Human milk has also been shown to have a specific inhibitory eff ct on E. coli in small intestine due to its high content of iron binding protein, predominantly hLF (Bullen, et al. (1972), British Med. J.. i, 69). Thus, the production of human lactoferrin in the milk of transgenic bovine species provides a source of human lactoferrin. Such lactoferrin may be purified from the transgenic milk for formulation purposes. Alternatively, the whole transgenic milk may be used, preferably after pasteurization, in either liquid or dried form. In addition, the beneficial action of human lactoferrin may be potentiated by combining the human lactoferrin or the transgenic milk containing it with human lysozyme. The human lysozyme may be simultaneously produced in the transgenic cow by introducing a second transgene simultaneously with the HLF transgene to produce a transgenic cow capable of producing more than one recombinant polypeptide in the transgenic milk. Alternatively, the transgenes may be sequentially introduced into bovine species. When such is the case, a transgenic bovine species is obtained containing one of the transgenes. Thereafter, embryonic cells, such as eggs, are obtained from the transgenic female and treated so as to incorporate the second transgene encoding the second polypeptide. Preferably, the egg is fertilized, followed bymicroinjection of the pronucleus of the zygote so obtained. It is to be understood that the foregoing combination of more than two recombinant polypeptides in transgenic bovine milk is not limited to the aforementioned human lactoferrin and lysozyme combination. Thus, the invention contemplatestheproduction of transgenicbovine species and transgenic milk wherein more than one recombinant polypeptide is produced by such a transgenic animal in the transgenic milk. The complete amino acid sequence of HLF has been determined (Metz-Boutigue et al. (1984) Eur. J. Biochem. 1451. 659-676). HLF comprises two domains, each containing one iron-binding site and one N-linked glycosylation site. These domains show homology between each other, indicative of an ancestral gene duplication and fusion event. In addition, HLF shares extensive homology with other members of the transferrin family (Metz-Boutigue, supra: Pentecost et al. (1987) J. Biol. Chem. 262. 10134-10139) . Location of the amino acids involved in the iron-binding sites has been determined by X-ray crystallography (Anderson et al. (1987) Proc. Natl. Acad. Sci. 84., 1769-1773). A partial cDNA sequence for neutrophil HLF was published by Rado et al. (1987) Blood 70. 989-993. There was a >98% agreement between the amino acid sequence deduced from the cDNA and that which was determined by direct analysis of lactoferrin from human milk. The structure of the iron- saturated and iron-free form of human lactoferrin have recently been published. (Anderson, e£ al. , (1989) J. Mol. Biol.209.711-734; Anderson, et al. (1990) Nature. 784-787.) As used herein, "human lactoferrin" comprises a polypeptidehaving the amino acid sequence substantially as described by Metz-Boutigue, et al. (1984) , Eur. J. Biochem. , 1451. 659-676 and as set forth in Fig. 2. It is noted, however, that an earlier partial sequence of the human lactoferrin sequence disclosed a number of discrepancies between the published sequence and that obtained herein. Specifically, the following discrepancies exist (amino acid numbering is from the sequence in Figure 1 with DNA position in parenthesis) : Accordingly, human lactoferrin is also defined by the sequence shown in Figure 1 which combines the sequence differences obtainedhereinwiththepublished sequence. The term human lactoferrin also includes allelic variations of either of these sequences or recombinant human lactoferrin variants wherein one or more amino acids have been modified by the substitution, insertion or deletion of one or more amino acid residues. In some instances human lactoferrin may be produced in milk with all or part of a secretory signal sequence covalently attached thereto. As used herein, a "human lactoferrin DNA sequence" is a DNA sequence which encodes human lactoferrin as defined above. Such a human lactoferrin DNA sequence may be obtained from a human mammary gland cDNA library or may be derived from the human genome. Example 2 herein describes the cloning and nucleotide sequence of human lactoferrin derived from a human mammary gland cDNA library. The DNA sequence of this human lactoferrin is shown in Fig. 1 and Fig. 2 and is substantially the same as that described by Rado, et al. (1987), Blood. 70. 989-993. The construction of plasmids containing an expressible transgene encoding hLF is described in the examples. One of these plasmids is cGPlHLF also sometimes referred to as 16,8HLF3) contains a transgene designed for tissue-specific expression in bovine mammary secretory cells. In a second embodiment of the invention, transgenes are provided for producing human serum albumin in the milk of transgenic bovine species. Human serum albumin is a serum protein which contains 584 amino acid residues (Minghetti, et al. (1986), J. Biol. Chem.. 261. 6747). It is the most abundant protein in human serum and performs two very important physiological functions. Serum albumin is responsible for about 80% of the total osmolarity of blood and it transports fatty acids between adipose tissues. Human serum albumin is' used primarily to expand plasma volume by restoring osmotic pressure in the circulatory system. Currently, a heat treated serum derived hSA fraction is infused in most shock and trauma victims, including most of the patients undergoing extensive surgery. HSA is presently derived from human blood plasma as a by-product from blood fractionation processes to obtain rare blood proteins such as factor VIII and IX. The recently developed technology of producing such factors by biotechnological means, however, threatens the source of human serum albumin. As used herein "human serum albumin" comprises a polypeptidehavingthe amino acid sequence substantially as that described by Minghetti, et al., ibid; Lawn, et al. (1981), Nucl. Acids Res.. 9_, 6103. Also included arevariations thereof includingrecombinanthuman serum albumin variants wherein one or more amino acids have been modified by the substitution, insertion or deletion of one or more amino acid residues. (Minghetti et al. (1986) J. Biol. Chem. 261. 6747-6757.) In some instances, human serum albumin may be produced in milk by expressing a transgene which contains DNA encoding the secretory signal sequence of hSA. Alternatively, human serum albumin may be produced in and secreted from liver cells of a transgenic animal utilizing a completely heterologous transgene comprising human genomicDNAencoding 5' expressionregulation sequences, the human serum albumin secretion signal and structural gene and 3' expression regulation sequences. As indicated in the Examples, transgenes containing this heterologous sequence were formed by in vivo homologous recombination of overlapping transgene fragments to reconstitute the hSA gene in the transgenic animal. The so formed transgenic animal producedhuman serum albumin in its circulatory system. As used herein, a "human serum albumin DNA sequence" is a DNA sequence which encodes human serum albumin as defined above. Such a human serum albumin DNA sequence may be obtained from λHAL-HAI, XHAL-3W and XHAL-HI4 as described by Urano et al. (1986) J. Biol. Chem. 261. 3244-3251 and Urano et al. (1984) Gene 32. 255-261 and in the Examples herein. The human serum albumin DNA sequence was cloned as described in Example 10 herein and subsequently manipulated to substitute for the human lactoferrin gene encoded in plasmid cGPlHLF (also referred to as pl6,8HLF4). From this plasmid a transgene is obtained containing 16kb of the 5• expression regulation sequence of the bovine αSl-casein gene, human serum albumin DNA sequence and approximately 8kb of the 3•-flanking region of the αSl-casein bovine gene. This transgene is used to microinject fertilized oocytes from bovine species. After early detection of transgenesis, blastocysts containing the hSA transgene are implanted into a recipient female bovine species and brought to term. The following is presented by way of example and is not to be construed as any limitation on the scope of the invention. EXAMPLE 1 Construction of a probe specific for bovine αSl-casein sequences. A. Isolation of Chromosomal DNA Placental tissue was obtained from the slaughterhouse. Surrounding connective tissue was removed and pieces of about 30 grams were quickly frozen in liquid N 2 . Chromosomal DNA was isolated as follows: 30 grams of tissue was homogenized (on ice) with 35 ml of Buffer 1 containing 300 mM Sucrose; 60 mM KCl; 15 mM NaCl; 60 mM Txis.HCl pH 8.2; 0.5 mM spermidine; 0.15 mM,spe_^ ine; 2 mM EDTA; 0.5 mM EGTA. 65 ml of icecold buffer 1 containing 1% NP40 was added and the mixture was incubated for five minutes on ice. After centrifugation for five minutes at 3000 xg the pellet was rinsed with buffer 1 containing 1% NP40. After repeating the centrifugation step the pellet was resuspended in 5 ml of buffer 1. 5 ml 0.5 M EDTA was quickly added. Final volume was now 15 ml. 0.15 ml of a 10% SDS solution was added. After mixing, RNAse A and Tl were added to final concentrations of 0.4 mg/ml and 6 u/ml respectively. After incubation at 37°C for three hours, Proteinase K was added to a final concentration of 0.1 mg/ml. This mixture was incubated for 15 hours at 37 β C. The mixture was then carefully extracted with phenol. The aqueous phase was isolated and 1/30 volume of 3M NaOAc pH 5.2 and one volume of isopropylalcohol was added. The precipitate (DNA) was rinsed with 70% ethanol and slowly dissolved in 0.5 ml of 10 mM Tris.HCl pH 8.0; 1 mM EDTA, at 4 β C. B. Amplification of Sequences from the 5'-flanking Region of the αSl-casein Gene Two DNA-primers were synthesized based on the sequence published by Yu-Lee et al. , (1986) Nucl. Acids Res. 14. 1883-1902. Primer 1 was located at position-681 relative to the major transcription initiation site and had the following sequence: 5'-TCC ATG GGG GTC ACA AAG AAC TGG AC-3' . (Seq. ID No.: 5) Primer ≠2 was located at position +164 relative to the major transcription initiation site and had the following sequence: 5'-TGA AGC TTG CTA ACA GTA TAT CAT AGG-3' (Seq. ID. No.: 6). The first eight nucleotides of this primer are not encoded by the bovine genome, but contain a Hindlll restriction site to facilitate subsequent cloning steps. These primers were annealed to the chromosomal DNA and extended in the presence of deoxynucleotidesbyTAQ-polymerase. Afterthreeminutes the mixture was denatured for one minute at 92°C, reannealed at 50 Q C for 1.5 minutes and again incubated at extension temperature (68°C) for 2 minutes. This cycle was repeated 30 times. After the last cycle DNA was checked for the presence of the expected EcoRI sites. Both the size of the fragment and the presence of EcoRI sites was as expected. The fragment was then treated with Klenow enzyme to repair any overhanging ends, treated with kinase to attach phosphate groups at the ends of the fragment, incubated at 65°C for 10 minutes to inactivate the kinase and klenow enzymes and finally digested with Hindlll. This fragment was then subcloned in pUC19 (Yanisch-Perron, et al. (1985) , Gene, 33, 103-109) digested with Smal and Hindlll. Formal proof of the identity of this fragment was obtained by sequencingparts of this subclone (after re-cloning into M13 vector) . The determined sequence was identical to the published sequence. This probe was then used to screen a bovine genomic library to obtain clones specific for the 5'-flanking region of the αSl-casein gene. C. Amplification of Sequences from the 3'-flanking Region of the αSl-casein Gene A similar approach was taken as described above. Two primers were designed based on the sequence published by Stewart et al (1984) Nucl. Acids Res.12., 3895-3907. The 5'-primer was located just downstream of the coding sequence starting at position 713 of the cDNA sequence. It had the following sequence: 5'-GAG GGA CTC CAC AGT TAT GG-3' (Seq. ID No. : 7). The other primer was located at position 1070 of the cDNA sequence and had the following sequence: 5'-GCA CAC AAT TAT TTG ATA TG-3' (Seq. ID No. : 8). These primers were annealed to the chromosomal DNA and the region between these primers was amplified as described above. The resulting fragment was «900 bp longer then expected. Sequence analysis showed that an intervening sequence of this size was present between nucleotide 737 and 738 of the cDNA. The amplified fragment was treated with Klenow-polymerase to repair any overhanging ends and treated with kinase to attach phosphate groups to the ends of the fragment. The fragment was then ligated into pUC19 previously cut with Smal. D. Screening of a Bovine Phage Library for αSl-casein Flanking Sequences A bovine genomic library, constructed in EMBL3, was obtained from Dr. M. Groenen, Agricultural University Wageningen, Netherlands, and was screened in the following way. The bacteriophage particle titre was determined on Escherichia coli MB406 a permissive host strain (Stratagene Inc.). For this, several dilutions of the phage stock were made in SM buffer (50 mM Tris.HCl pH 7.5, 100 mM NaCl, 10 mM MgS04, 0.01% gelatin) and mixed with 200 μl MB406 (O.D. 550 = 0.9); after 20 minutes at 37°C, 3 ml top agarose (Luria- Bertani medium, 0.8% agarose, 10 mM MgCl 2 ) was added and this was plated on LB plates and incubated overnight at 37°C. Approximately 600,000 phages were then plated by adding the required amount of phage stock to 400 μl MB406. The subsequent plating was as described as above. The next step was transfer of the phage to nitrocellulose filters. Plates were placed at 4 β C for one hour. Nitrocellulose filters (S&S) were placed on the top agarose layer and exact position was marked. After lifting, the filters were soaked for (1) 30 minutes in denaturation buffer (1.5M NaCl, 0.5M NaOH) ; (2) 5 minutes in neutralizing buffer (1.5MNaCl, 0.5MTris.HCl pH 8.0) . After rinsing with 2xSSPE (360 mM NaCl, 20 mM NaH 2 P0 4 , 2 mM EDTA) , the filters were baked under vacuum at 80°C for two hours. Prehybridization of the filters was performed in a buffer containing 50% formamide, 5x Denhardt's solution (0.1% Ficoll, 0.1% polyvinylpydrolidone, 0.1% bovine serum albumin) , 5xSSPE, 0.1% SDS and 100 μg/ml denatured salmon sperm DNA at 42°C for two hours. Hybridization was performed in same buffer at 42°C overnight in a shaking waterbath. The probe, generated as previously described, was labelled using the Random Primed labelling kit from Boehringer Mannheim. After overnight hybridization the filters were washed three times with 2xSSC, 0.1% SDS at room temperature. Overnight exposure of Kodak XAR films was performed with amplifying screens (Dupont) at -70 β C. Putative positives were plugged out of the plates and put overnight in SM buffer at 4°C. These were plated out as described above and DNA was isolated following the plate lysate method (Maniatis, T., et al. (1982), Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, N.Y.). 5 ml SM buffer was added to the top agarose layer; after two hours gentle shaking buffer was removed and spun at'4000 rpm at 4 β C for 10 minutes. Supernatant was transferred to sterile tubes and RNase A and DNasel (both final concentration lμg/ml) was added, this was incubated at 37°C for 30 minutes. One volume of a 20% polyethyleneglycol, 2.5 M NaCl solution was added and put on ice for one hour. Centrifugation at 4000 rpm for 30 minutes at 4°C left precipitated bacteriophage particles. These were resuspended in 500 ml SM buffer, SDS (final concentration 0.1%) and EDTA (final concentration 5 mM) was added, this was incubated at 68 β C for 15 minutes. Protein was removed with one phenol and one chloroform extraction step. Precipitation of phage DNA was performed with one volume isopropanol. Phage DNA was washed once with 70% ethanol and dissolved in 50 ml Tris.HCl pH 7.5, 1 mM EDTA buffer. Restriction enzyme analysis, agarose gel electrophoresis, transfer of DNA from gel to nitrocellulose filter and Southern blotting were all done according to standard procedures (Maniatis (1982) , Mc ocular Cloning: A Laboratory Manual) . Hybridization wiτh probes (described hereinafter) was performed according to the same procedure as the screening conditions described above. E. Isolation of Clones Containing 5'-flanking Region of Bovine Sl-casein Three putative clones were identified using the probe and procedures as described above. After another round of screening, clean recombinant bacteriophage was analyzed. Digestion of cloned DNA with Sail. EcoRI and Sail/EcoRI (doubledigestion) andhybridizationwiththe probe described above showed identical inserts in all three clones. The insert consisted of an 18kb (partial Sau3A fragment excised with Sail) . Transciptional orientation in the clone was determined with hybridization of above described restriction fragments with (1) probe 1 described above, and (2) the Ncol-Nsil fragment of probe 1. This showed a region of about 16kb upstream of transcription start. Downstream from the transcription start was another 1.9kbp. Sequencing of part of the latter region showed the presence of exon 2 and part of intron 2 of the bovine αSl-casein gene. Additional sequencing of the region-103 - +300 confirmed the identity of the clone. The ethidium-bromide pattern of the described restriction fragments also showed the orientation of the clone in the EMBL vector. Subsequent analysis of the clone with the following restriction enzymes (Ncol. Pstl, Kpnl. BamHI. Hindlll. Bglll) resulted in the restriction map of 5' flanking region of bovine Sl-casein gene as shown in Fig. 3. F. Isolation of Clones Containing 3'-flanking Region of Bovine αSl-casein Duplicate nitrocellulose filters from the initial phage plating used for isolating 5' clones were screened with the 3• αSl-casein probe using the same hybridization conditions previously described. Eight positive clones were identified after two rounds of screening. Phage DNA was prepared as described. Subsequent restriction digests with Sail. EcoRI. and Sal/EcoRI and Southern hybridization with the 3* Sl probe showed identical inserts in seven of the eight clones. One clone containing an 18.5kb EcoRI insert was further analyzed with the restriction enzymes Bstell and Ba HI. A restriction map of that clone is shown in Fig. 4. EXAMPLE 2 Cloning of Human Lactoferrin Gene A. Materials Restriction endonucleases, T4 ligase, and T7 polynucleotide kinase were obtained from Boehringer- Mannheim, New England Biolabs, or Bethesda Research Laboratories. Radio-isotopes were purchased from Amersham. A human mammary gland cDNA library in bacteriophage λgtll was obtained from Clontech, Inc., Palo Alto, Calif. B. Isolation of the Human Lactoferrin Gene The human mammary gland library was screened by standard plague hybridization technique (Maniatis, et al. (1982) Molecular Cloning; A Laboratory Manual) with three synthetic oligomers. Two of the oligomers were 30-mers corresponding to the cDNA sequence of Rado et al. , supra. at amino acid positions 436-445 and 682-691. The third was a 21-mer "best guess" probe based on human codon bias and coding for amino acid sequence of HLF between amino acid residues 18 and 24. Respectively, they were: (1) 5 » -CTTGCTGTGGCGGTGGTTAGGAGATCAGAC-3 ' (Seq. ID NO.: 9) (2) 5'-CTCCTGGAAGCCTGTGAATTCCTCAGGAAG-3 ' (Seq. ID No. : 10) , and (3) 5•-ACCAAGTGCTTCCAGTGGCAG-3 » ( Seq. ID No. : 11). The probes were radiolabeled (Crouse et al. (1983) Methods Enzymo1. 101. 78-98) and used to screen duplicate filters. Filters were washed at a final stringency of 2 X SSC, 37 β C. C. Nucleotide Sequence Analysis DNA fragments were isolated by use of low-melting agarose (Crouse et al, supra) and subcloned into bacteriophase M13mpl8 or M13mpl9 (Messing et al. (1983) Methods Enzymol. 101, 20-78) . The sequence was determined using the Sequenase enzyme (modified T7 DNA polymerase) (Tabor et al. (1987) Proc. Natl. Acad. Sci. USA 84. 4767-4771). All reactions were carried out according to the manufacturer's specifications (US Biochemicals) . The sequence is shown in Fig. 1. The hLF sequence was digested with Hindlll and EcoRI (present in the surrounding phage sequences) and subcloned into the Hindlll and EcoRI site of pUC19 to form pUS119 Lacto 4.1. This clone contained the entire coding sequence of the mature form of hLF, but lacked the complete signal sequence. EXAMPLE 3 Construction of bovine αSl-casein CAT vectors In order to determine whether the αSl-casein fragments obtained in Example 1 had promoter and other properties needed to express a heterologous gene, expression plasmids were constructed containing variable amounts of 5-' and 3'-flanking regions from the αSl-casein gene. The chloramphenicol Acetyl transferase gene (CAT) was used as a heterologous gene in these vector constructs. The CAT gene is useful to detect the expression level for a heterologous gene construct since it is not normally present in mammalian cells and confers a readilydetectable enzymatic activity (see Gorman, C.N., et al. (1983) , Mol. Cell. Biol.. £, 1044-1051) which can be quantified in the cells or animals containing an expressible gene. A. DNA sequences. 681 bp of a αSl-casein pr .moter plus the first on- coding exon plus approximately 150 bp of the first intervening sequence (IVS) were isolated from a 5'- flanking genomic clone from Example 1 by PCR amplification as an Ncol-Hindlll fragment (approximately 830 bp) . This fragment is identified as fragment 1 in Fig. 5A. The primer sequences consisted of: 5•-TCCATGGGGGTCACAAAGAACTGGAC-3 » (Seq. ID No.: 12) and 5•-TGAAGCTTGCTAACAGTATATCATAGG-3' (Seq. ID No. : 13) that were designed from a sequence published by Yu-Lee et al. (1986) Nuc. Acids Res. Ii, 1883-1902. Approximately 1.6kb (fragment 2, Fig. 5A) of αSl-casein 3'-flanking sequence was isolated by PCR amplification from a bovine 3'-flanking genomic clone from Example 1. This region contained the previously described splice within the 3' untranslated region of αSl-casein gene. Fragment 2 was subcloned into the Smal site of pUC19. The primer sequences consisted of: 5'-GAGGGACTCCACAGTTATGG-3• (Seq. ID No.: 14) and 5'-GCACACAATTATTTGATATG-3' (Seq. ID No.: 15) that were designed from a sequence published by Stewart et al. (1984) Nucl.Acids Res. 12, 3895-3907. A hybrid splicing signal comprising the 3' splice site of an immunoglobulin gene (Bothwell et al. (1981) , Cell, 2A. 625-637) was synthetically prepared and inserted into pUC18 along with unique restriction sites flanking either side to produce pMH-1. This plasmid is shown in Fig. 6. Ncol and Hindlll sites were designed such that ligation with fragment 1 from the bovine 5' genomic clone would result in the functional hybrid splice sequence. See Fig. 11. A polyadenylation sequence was obtained from SV40 virus as a BamHI-Dral fragment (fragment 3 in Fig. 5A) isolated from pRSVcat (Gorman, CM., et al. (1982), Proc. Natl. Acad. Sci.. 79. 6777-6781) . A bacterial CAT coding sequence was subcloned into pUC19 as a Pstl-BamHI fragment. B. Construction of pS13'5'CAT Fragment 1 of αSl-casein promoter was subcloned into pMH-1 (Fig. 6) between the Ncol and Hindlll sites to form pMHS15'flank. The SV40 polyadenylation sequence (fragment 3) was subcloned as a BamHI-Dral fragment into pUC19 immediately 3' to the 3' αSl-casein flanking sequence (fragment 2) to form pUC19 3' UTR/SV40. This allowed for the removal of a continuous EcoRI-Sall fragment (containing the 3'-flanking sequence and poly (A) sequence) that was subcloned into pMH-1 to derive pMHS13'UTR (Fig. 5B) which was used later to construct pMHSI 3* UTR hlf which contains sequences encoding human lactoferrin. The EcoRI-Sall sequence (fragments 2 and 3) were subcloned into the EcoRI-Sall sites of pMHS15*flank to form pS13'5 » flank. The Pstl-BamHI CAT fragment (fragment 4 in Fig. 5B) , after blunting the BamHI site with Klenow, was subcloned into pS13'5'flank (Fig. 5B) between the Pstl and Smal sites to form pS13'5'CAT. C. Construction of PS15'CAT The CAT fragment (fragment 4 in Fig. 5B, Pstl-BamHI) and SV40 polyadenylation fragment (fragment 3 in Fig. 5A, BamHI-Dral) were subcloned into the Pstl and Smal sites of pMHS15'flank to form pS15'CAT (Fig. 5C) . D. Assay for CAT Production Each of these CAT plasmids were transfected into human 293S cells (Graham, F.L. , et al. (1977), J. Gen. Virol.. 36. 59-72) by the calcium phosphate co-precipitation method (Gorman, CM., et al. (1983), Science. 221. 551; Graham, F.L., et al. (1973), Virology. 52. 456-467). Cells were harvested 44 hours after transfection and cell extracts were assayed for CAT activity (Gorman, CM., et al. (1982), Mol. Cell. Biol.. £, 1011; deCrombrugghe, B., et al. (1973), Nature [London], 241, 237-251, as modified by Nordeen, S.K., et al. (1987), DNA, 6., 173-178) . A control plasmid expressing CAT driven by the Cytomegalovirus Immediate early promoter (Boshart, M. , et al. (1985), Cell. 41. 521) was transfected into human 293 S cells to assay for transfected efficiency. pS13*5'CAT was expressed in these cells at a level which was approximately 30-100 fold lower than the control plasmid, but significantly higher than background. Primer extension analysis indicated that transcription had initiated predominantly in the expected region. When pS15'CAT was transfected into 293S cells, expression was also detected. EXAMPLE 4 Bovine Sl-casein/human lactoferrin expression cosmid cGPlHLF A. Construction of DNA Sequences. 16kb of bovine αSl-casein 5'-flanking sequence from Example 1 was isolated from the bovine genomic library (phage GP1) as a Sall-Bglll fragment. The Bglll site lies at the junction of the first intron and second exon of the αSl-casein gene. Bovine αSl-casein signal sequence (Stewart et al. (1984) Nucl. Acids Res. 12, 3895) was prepared from synthetic DNA synthesized on a Cylone Plus® DNA Synthesizer (Millgen/Biosearch I) and contained the entire signal sequence plus Xhol and Cla I sites attached to the 5'-end, and Nael to the 3'-end (fragment 8, Fig. 7B) . Cleavage of pUC119 Lacto 4.1 with Eael precisely opened the plasmid at the codon for the first amino acid of mature hLF. Treatment with Klenow was used to fill in the overhanging 5'-end. Further digestion with Accl and EcoRI gave two fragments: (a) an Eael-Accl fragment containing the first 243 bp of mature hLF (fragment 5, Fig. 7C) , and (b) a contiguous Accl-EcoRI fragment (fragment 6, Fig. 7C) of 1815 bp that contained all but five terminal codons of the remaining coding sequence. A synthetic linker was prepared that contained the last five codons of hLF beginning at the EcoRI site and extending for four bases beyond the stop codon. A Kpnl site was added to the 3'-end (fragment 7 in Fig. 7C) . An 8.5kb EcoRI 3'-fragment was isolated from the bovine genomic library (Fig.4) containing sequences beginning just downstream of the coding region of αSl-casein and a BstEII site approximately 350 bp from the 5'-end. This fragment was subcloned into pMH-1 at the EcoRI site to form pMH3'E10 (Fig. 7A) . A Sail site is adjacent to the 3'-EcoRI site in pMH3'E10. B. Construction of cGPlHLF The hLF 3'-linker (fragment 7, Fig. 7C) was subcloned into the EcoRI-Kpnl sites of pMH3'UTR (Fig. 7A) to produce pMH3'UTRhLF2linker (Fig. 7A) . The synthetic bovine αSl-casein signal sequence (fragment 8) was then subcloned into the Xhol and Smal sites of pMH3'UTRhLF2linker to make pS13'hLFl/2L (Fig. 7B) . The two hLF coding fragments (fragments 5 and 6 in Fig. 7C) were subcloned into the Nael " and EcoRI sites of pS13'hLFl/2L (Fig. 7B) to make pS13'UTRhLF (Fig. 7C) . The large αSl-casein 3'UTR fragment from pMH3'E10 (Fig. 7A) was isolated as a BstEII-Sall fragment and subcloned into the same sites of pS13'UTRhLF to form phLF3'10kb (Fig. 7D) . Cosmid cGPlHLF was prepared from a 3-way ligation (Fig. 7F) : (1) the 16kb 5'-flanking sequence from phage GPl (Example l. Fig. 3) was modified by attaching two linker adapters. The Sail site at the 5'-end was ligated to a Notl-Sall linker. The Bglll site at the 3'-end was ligated to a Bglll-Xhol linker; (2) the hLF coding region, flanked on the 5'-end by the αSl-casein signal sequence and on the 3'-end by approximately 8.5kb of αSl-casein 3'-flanking sequence, was isolated as a Xhol-Sall fragment from phLF3'10kb. The Sail site at the 5'-end was ligated to a Sall-Notl linker; (c) Cosmid pWE15 (Stratagene, Inc.) was linearized with Notl. Fragments from (a) , (b) , and (c) were ligated together and transfected into bacteria using commercial lambda packaging extracts (Stratagene, Inc.) to produce cGPlHLF. EXAMPLE 5 Bovine αSl-casein/hLF expression plasmids. A. Construction of pS13'5'hLF The Hindlll-Sall fragment of pS13'UTRhLF was subcloned into the same sites in pMHS15'flank to form pS13'5'hLF (Fig. 7E) . This plasmid contains 681 bp of bovine αSl-casein promoter sequence, the α__l-casein/IgG hybrid intron, the αSl-casein signal sequence, the hLF coding region, approximately 1.6kb of αSl-casein 3'-flanking sequence, and the SV40 late region polyadenylation sequence. B. pS15'hLF Plasmid pS13'5'hLF (Fig. 7E) was cut with Kpnl and BamHI which border the αSl-casein 1.6kb 3'-flanking sequence. The larger vector fragment was purified, made blunt ended with Klenow, and self-ligated to form pS15'hLF. C. Radioimmunoassav for hLF An immunoglobulin-enriched fraction of ascites fluid of a monoclonal antibody against human lactoferrin, which does not cross-react with the bovine or murine protein, was prepared by 50% ammonium sulfate precipitation and coupled to CNBr-activated Sepharose 4B ( 20 mg of protein to 1 g of Sepharose) . The Sepharose beads were suspended (2 mg/ml) in phosphate-buffered saline (PBS; 10 mM sodium phosphate, 0.14 M NaCl containing 10 mM EDTA, 0.1% ( w /v) Polylorene and 0.02% ( w /v) NaN 3 , pH 7.4. Sepharose suspensions (0.3 ml) were incubated for five hours at room temperature by head-over-head rotation with samples (usually 50μl) in 2-ml polystyrene tubes. Sepharose beads were then washed with saline (five times with 1.5 ml) and incubated for 16 hours at room temperature with 50μl (IkBq) of 125 I-labeled-affinity- purified polyclonal rabbit anti human lactoferrin antibodies, together with 0.5 ml of PBS, 0.1% ( w /v) Tween-20. Thereafter the Sepharose was washed again with saline (four times with 1.5 ml) and bound radio activity was measured. Results were expressed as percent binding of the labelled antibodies added. Levels of lactoferrin in test samples were expressed in nanomolar, using purified human milk lactoferrin as a standard (serial dilutions in PBS, 10 mM EDTA, 0.1% ( w /v) Tween-20. Repeated testing of standard on separate occasions revealed that this RiA was highly reproducible, intra- and inter assay coefficients of variation ranged from 5-10%. As little as 0.1 nanogram human lactoferrin is easily detected by this RIA. D. Expression in 293S cells 293S cells were transfected with the above hLF plasmids as described (lμg of a CMV-CAT plasmid was co- transfected as control for transfection efficiency) . Forty-four hours after transfection medium was removed from the cells and assayed for hLF as described supra, RNA was isolated as described by Stryker, et al. (1989) EMBO J. 8., 2669. The results can be summarized as follows: 1. Transfection efficiencies are identical for the two hLF plasmids; 2. hLF is expressed in the cells and secreted into the medium. In both cases, the levels are about 0.4μg/ml medium using about 3x 10 6 cells 3. The proteins behave identical to hLF in a human milk sample in a dose response assaymeasuring the amount of 125I- anti-lactoferrin bound as a function of the amount of sample used. 5 4. The protein has about the same size ( * 80kD) as in a human milk sample as judged by Western blotting. 5. The hLF RNA produced in the cells has the correct size and its level is similar for both plasmids as judged by Northern - blotting. 0 These data indicate that these two expression plasmids are able to express hLF. By all standards used so far, the protein is identical to hLF present in human milk. The heterologous signal sequence is functional in that c it promotes secretion of the protein from the cells into 5 the medium. Further, the casein regulatory sequences used in these plasmids are able to promote expression of a heterologous gene. EXAMPLE 6 In vitro Maturation, Fertilization 0 and Culture of Bovine Oocytes Immature oocytes are obtained in large quantity (400-600/day) by aspirating follicles of ovaries obtained at abbatoirs. Immature oocytes are cultured 5 for a period in vitro before they are competent to be fertilized. Once "matured", oocytes are fertilized with sperm which has also been matured, or "capacitated" in vitro. The pronuclei of the fertilized oocyte is then injected with the transgene encoding for the expression 30 and secretion of human lactoferrin. Zygotes resulting from this in vitro fertilization and microinjection are then cultured to the late orula or blastocyst stage (5-6 days) in medium prepared, or "conditioned" by oviductal tissue. Blastocysts are then transferrednon- 35 surgically to recipient cattle for the balance of gestation or analyzed for integration of the transgene as described herein. In vitro maturation (IVM) . Ovaries are obtained immediately after slaughter at local abbatoirs and oocytes are recovered. Alternatively, oocytes are obtained from living cattle by surgical, endoscopic, or transvaginal ultrasonic approaches. In all cases, oocytes are aspirated fron ovarian follicles (2-10 mm diameter) . After washing, oocytes are placed in a maturation medium consisting of M199 supplemented with 10% fetal calf serum, and incubated for 24 hours at 39 β C Sirard et al. (1988) Biol. Reprod. 39, 546-552. 3.. i .1 • . In vitro fertilization (IVF) . Matured oocytes, are fertilized with either fresh or thawed sperm. Sperm are prepared for fertilization by first obtaining a population of sperm enriched for motility by a "swim-up" separation technique (Parrish et al. (1986) Theriogenology 25.591-600) . Motil sperm are then added to a fertilization media, consisting of a modified Tyrode's solution (Parrish et al. (1986) supra.) supplemented with heparin to induce sperm capacitation (Parrish et al. (1988) Biol. Reprod. 3_8, 1171-1180). Capacitation constitutes the final sperm maturation process which is essential for fertilization. Sperm and oocytes are co-cultured for 18 hours. A useful feature of this IVF method is that (in the case of frozen sperm) consistent, repeatable results are obtained once optimal fertilization conditions for a particular ejaculatehave been defined (Parrish et al. (1986) supra.) . In vitro culture (IVC) . Conventional culture systems, which support development of murine, rabbit, or human ova, do not support development of bovine embryos past the 8-16 cell stage. This problem has been overcome by pre-conditioning culture media with oviductal tissue. Oviduct-conditioned medium will support bovine embryos past the 8-16 cell stage to the blastocyst stage in vitro (Eyestone and First (1989) J. Reprod. Fert. 85. 715-720) . Bovine embryos have proved refractory to in vitro culture. This in part stems from the existence of a "block" to cleavage in vitro at the 8-16 cell stage. This block may be alleviated by culturing embryos in the oviducts of rabbits (reviewed by Boland (1984) Therioqenology 21. 126-137) or sheep (Willadeen (1982) in: Mammalian Egg Transfer, (E. Adams, ed. , pp. 185-210)); Eyestone etal. (1987) Theriogenology 28. 1-7) . However, these in viv alternatives have been less than ideal, in that: (1) they require the maintenance of large numbers of recipient animals, (2) they require surgery to gain access to the oviducts for transfer, and a second surgery (or sacrifice) to recover the embryos, (3) all transferred embryos are seldom recovered, and (4) access to embryos during culture for observation or treatment is entirely precluded. The lack of in vitro culture systems has hampered the development of various manipulation techniques (such as gene transfer by pronuclear injection) by preventing accumulation of basic information of the chronology and ontogeny of bovine development, and by complicating the process of culturing embryos to a stage compatible with non- surgical embryo transfer and cryopreservation techniques (e.g., late blastocyst stages) . Bovine embryos did not yield to attempts to culture them in vitro past the 8-16 cell "block" until Camous et al. (1984) J. Reprod. Fert. 72. 479-485 demonstrated cleavage to 216 cells when embryos were co-cultured with trophoblastic tissue. The co-culture procedure was extended to oviductal tissue, based on the ability of homo- or hetero-oviducts to support development from zygote to blastocyst. Thus, bovine embryos co-cultured with oviductal tissue, or in medium conditioned by oviductal tissue, developed from zygote to blastocyst in vitro (Eyestone and First, (1989) J. Reprod. Fert. 85. 715-720; Eyestone W.H. (1989) "Factors affecting the development of early bovine embryos in vivo and in vitro." Ph.D. Thesis, University of Wisconsin) . Blastocysts have been produced in this system after superovulation and artificial insemination, or by in vitro maturation (IVM) , and fertilization (IVF) of immature oocytes. Blastocysts produced in this fashion resulted in pregnancies and live calves after transfer to recipient animals. The results obtained were as follows: Therefore, from an initial daily harvest of 500 oocytes, it is expected the approximately 55 pregnancies will result. Preparation of Oviduct Tissue Co-Culture and Conditioned Medium 1. Obtain bovine oviducts after slaughter or by salpingectomy. 2. Harvest lumenal tissue by scraping intact oviduct gently with a glass slide. 3. Wash tissue 5 times in 10 mlmodified tyrodes- hepes solution (Parrish et al. (1988) Biol. Reprod. 38. 1171-1180) . 4. Resuspend final tissue pellet in M199 + 10% fetal calf serum at a ratio of 1 volume tissue:50 volumes of media. 5. Tissue suspension can be used for embryo-co- culture. 6. Alternatively, media may be conditioned for 48h; after centrifuging the suspension, the supernatant may be used as embryo culture medium. Conditioned medium may be stored at -70°C, if desired. Conditioned medium should be used at full strength for embryo culture (no dilution) (Eyestone (1989) ibid) . EXAMPLE 7 Microiniection of hLF Transgene into Bovine Pronuclei The DNA fragment containing the hLF expression unit is excised from the vector by digestion with the appropriate restriction enzyme(s) and separated on agarose gels. The fragment is purified by electroelution, phenol and chloroform extraction and ethanol precipitation (Maniatis et al.) . The DNA fragment is dissolved in and dialyzed in 10 mM tris, 0.1 mM EDTA pH 7.2 at a concentration of 1 to 2μg/ml. Microinjection needles are filled with the dialyzed DNA solution. Before invitro fertilization, cumulus cells are removed from the egg by either vortexing at maximal speed for 2 minutes or pipetting the eggs up and down several times in a standard micropipet. Bovine pronuclei are injected in principle as murine pronuclei (Hogan, B. et al. (1986) in: Manipulating the mouse embryo, Cold Spring Harbor Laboratory) with an additional centrifugation step in order to visualize the pronuclei. The injection takes place 18-24 hours after fertilization. The time varies depending on the bull used as a source of semen. Different batches of semen cause the nuclei to become visible at different times. Bovine oocytes, matured and fertilized in vitro, are spun in an eppendorf tube in 1 ml of tyrodes-hepes solution (Parrish (1987)) at 14500 g for eight minutes (Wall et al. (1985) Biol. Reprod. 31, 645-651) . The embryos are transferred to a drop of tyrodes-hepes solution on a microscope slide covered with paraffin oil. Using a hydraulic system the oocytes are fixed to the egg holder in such a way that both the pronuclei are visible (using interference-contrast or phase contrast optics) . If necessary, the oocytes are rolled to change their position on the egg holder to visualize the pronuclei. The injection needle is brought into the same sharp focus of one of the pronuclei. The needle is then advanced through the zona pellucida, cytoplasm into the pronucleus. A small volume of 1-3 pi is injected (containing 20-100 DNA copies) into the pronucleus either by using a constant flow or a pulse flow (using a switch) of DNA solution out of the needle. Alternatively, two cell stage embryos are spun as described and the nuclei of both blastomers are injected as described. The injected embryos are then transferred to a drop of co-culture medium as described in Example 6 in order to develop to the morula or blastocyst stage. EXAMPLE 8 Earlv Detection of Transgenesis with hLF Transgene Upon the microinjection of a construct, the oocyte is cultured. A proper site of each embryo is cleaved and subjected to lysis (King, D. et al. (1988) Molecular Reproduction and Development 1, 57-62) , proteolysis (Higuchi, R., (1989) "Amplifications (A forum for PCR Users." 2.. 1-3) and DPNI digestion. PCR is performed as described previously (Ninomiy, T. et al. (1979) Molecular Reprod. and Devel. 1, 242-248) with sets of two primers, one in αSl and the other in hLF cDNA sequence. For example, in a PCR where the forward primer (30mer) αSl sequence is ATG AAA CTT ATC CTC ACC TGT CTT GTG (Seq. ID No.: 16) and the reverse primer (30mer)in hLF sequence is GGG TTT TCG AGG GTG CCC CCG AGG ATG GAT (Seq. ID No. : 17) ; 971- 1000 of Figure 1) , a 990 bp fragment will be generated. This fragment contains the hitherto inactivated DpNI site by loss of adenosine-methylation, at 934 bp away from the start of the forward primer. EXAMPLE 9 Production of hLF in Milk of Bovine Species Bovine morula developed from microinjected oocytes are split according to the method of Donahue (Donahue, S. (1986) Genetic Engineering of Animals, ed. J. Warren Evans et al.. Plenum) . One half of the morula is kept in culture to develop into blastocysts. The other half is subjected to the DNA analysis as described in Example 8. When the result of this analysis is known, the morula kept in culture are developed into a blastocyst or as a source for nuclear transfer into enucleated zygotes. Blastocyst transfer into synchronized cows is performed according to the method of Betteridge (Betteridge, K.J. (1977) in: Embryo transfer in farm animals: a review of techniques and applications) . hLF is detected in the milk of lactating transgenic offspring using the RIA of Example 5. EXAMPLE 10 Bovine aSl-casein/hSA Expression Plasmids Three overlapping phage clones that contain the complete hSA gene are used to construct an expression vector for hSA. They are designated λHAL-HAl, XHAL-3W and λHAL- H14. They are described in Urano, et al. (1986), J. Biol. Chem.. 261. 3244-3251; and Urano, et al. (1984), Gene. 32. 255-261. The sequence of the gene plus some surrounding regions is published in Minghetti, et al. (1986), J. Biol. Chem.. 261, 6747-6757. A single phage containing the complete hSA gene is constructed as follows: Clone HA-1 is cut with BstEII and Ahall. The «1400 bp fragment running from position 1784 (in the first exon, just downstream of the ATG) to 3181 is isolated and a synthetic linker is attached to the BstEII site at the 5 • end containing the first few amino acids that are cut off with BstEII as well as the sequence surrounding the ATG as well as a few convenient restriction sites. This fragment is called fragment ≠l. Clone 3W is cut with Ahall and Sa the «13.lkb fragment running from position 3181 to 16322 is isolated and a synthetic linker is attached to the Sad site to facilitate cloning in phage EMBL3. This fragment is called fragment #2. These two fragments are ligated and cloned in phage EMBL3. After identification of the correct phage, a fragment running from just upstream of the BstEII site (where unique restriction sites have been introduced) to the Sad site are isolated and ligated from a Sad to Sail fragment (running from position 16322 to «21200 isolated from clone H-14. These two fragments are then ligated and cloned in EMBL4. After cutting with Clal (just upstrea of the BstEII site, newly introduced) and BamHI (just downstream of the Sail site in the phage DNA) this new clone yields a fragment containing the complete hSA gene with about 2.5kb 3'-flanking sequence. To construct an expression vector for hSA cosmid cGPlHLF is partially digested with Clal and BamHI. This removes the signal sequence, the coding sequence of hLF, the 3'- UTR and poly(A) addition region of αSl-casein as well as a small region 3* of the casein gene. This is ligated to the hSA fragment described above and the resulting cosmid is called cGPlHSA. The expression vector so formed contains, (1) 16kb of promoter sequences derived from the αSl-casein gene, (2) the first exon and intervening sequence of this gene both present in GP1, (3) the signal sequence of the hSA gene the complete genomic gene coding for hSA including 2.5kb downstream of that gene, and (4) «8kb of 3'-flanking sequence derived from the αSl-casein gene. This transgene is used to produce transgenic bovine species producing hSA in their milk in a manner analogous to that used to produce hLF in the milk of bovine species. EXAMPLE 11 Purification of HSA from the Milk of Bovine Species Purification of heterologous proteins from milk is facilitated by the fact that, following casein precipitation, those proteins, for the most part, are found in the whey fraction which is less contaminated than the production media used in microbial or cell- based systems. Chromatographic techniques are preferred for the purification of hSA from cow milk. This approach produces a better recovery and higher albumin purity as well as a lower content of albumin polymers as compared with ethanol fractionation (Curling (1980) in: "Methods of Plasma Protein Fractionation", Curling, ed. , Academic Press London, UK; Curling et al. (1982) J. Parenteral Sci. Technol. 36, 59; Berglof et al. and Martinache et al. (1982) Joint Meeting IHS-ISBT, Budapest) . The specific transport role of hSA as well as its major role in maintaining intravascular osmotic pressure may also be better preserved upon chromatographic purification (Steinbruch (1982), Joint Meeting ISH-ISBT, Budapest). The following steps are used to recover^hSA produced in the milk of transgenic cows: 1. Precipitation of caseins (about 80% of milk protein) and essentially all the milk fat at pH 4.5 and/or by adding chymosin. The whey fraction contains the albumin; 2. Affinity-chromatography of albumin on Cibacron blue 3GA-Sepharose CL-6B (Harvey (1980) in: Methods of Plasma Protein Fractionation, op. cit.) This step serves both to remove proteins other than albumin and to decrease the volume to be handled about 30-fold. Albumin is eluted from this matrix with 0.15 M NaCl and 20 mM sodium salicylate at pH 7.5; 3. Buffer-exchange on Sephadex G-25: desalting into 0.025 M sodium acetate, adjustment to pH 5.2, followed by filtration; 4. Anion-exchange chromatography on DEAE-Sepharose CL-6B. Desorption of albumin at pH 4.5; 5. Cation-exchangechromatographyonCM-Sepharose CL- 6B. Albumin elution with 0.11 M sodium acetate. pH 5.5 and concentration of albumin at a 6% (w/v) solution by ultrafiltration; and 6. Gel filtration on Sephacryl S-200. Fraction of high-molecular weight protein (e.g. albumin polymers, pyrogens) is discarded. The main fraction (albumin monomers) is concentrated by ultrafiltration and formulated. It is to be noted that steps 3-6 are essentially identical to the method described by Curling and others (Curling (1980) op. cit.; Curling et al. (1982) op. cit.; Berglδf et al. (1982) op. cit.) for the purification of hSA from plasma. EXAMPLE 12 Transgenic Mice Containing the Human Serum Albumin (hSA) Transgene Generated by Homologous Recombination Three overlapping genomic hSA clones were used to generate the hSA gene in transgenic mice, λHAL-HAl, XHAL-H14 and XHAL-3W, are shown in Figure 8 as reported by Urano, et al. (1984) , Gene. 32. 255-261 and Urano, et al. (1986), J. Biol. Chem.. 2613244-3251. Briefly, a genomic library was constructed from a partial EcoRI digest of human fibroblast DNA. For the clones XHAL-H14 and XHAL-3W, this library was screened with 32 P-labeled human albumin genomic clones by hybridization in 1 M NaCl, 50 mM Tris-HCl (pH 8.0) , 10 mM EDTA, 0.1% SDS, 100 ug/ml of sheared salmon sperm DNA and lOx Denhardt's solution at 65° C overnight after prehybridization in 3x SSC and lOx Denhardt's solution. Following hybridization, filters were washed in 0.2x SSC and 0.1% SDS at 65° C The isolation of the λHAL-HAl clone was identical except that a 0.9 kb BglH-EcoRI fragment from the 5' end of XHAL-3W was used to screen the human fibroblast library. These three hSA phage clones were used to generate three overlapping linear DNA fragments, which in composite comprised the whole HSA gene and flanking regions. The 5' most fragment I was a EcoRI-EcoRI fragment isolated from λHAL-HAl; the middle fragment II was a Acyl (=AhaII) -Sad fragment of λHAL-3W; and the 3 » most fragment III was a Xhol-Sall fragment of λHAL-H14 (Fig. 7) . The fragments were treated with klenow DNA polymerase and dNTP's to fill in overhanging sticky ends. In some experiments, the blunt ended fragments were then treated with bacterial alkaline phosphatase to remove the 5' phosphate groups from each fragment. The overlapping DNA fragments were next concentrated then coinjected into the male pronuclei of fertilized mouse eggs,according to published methods (Hogan, et al. (1986) in "Manipulating the Mouse Embryo: A Laboratory Manual", Cold Spring Harbor Laboratory) . While the number of molecules injected varied from «25 to «100 per egg cell, the ratio of the individual fragments was approximately 1:1:1. Embryos were implanted into the uteri of pseudo pregnant female mice according to the methods of Hogan, et al., supra. To assay correct homologous recombination of the three overlapping fragments and integration of the nascent transgene into the mouse genome, genomic DNA from the newborn pups was subject to the following specific digestions followed by Southern hybridization with HSA cDNA probes: Bst EH: cuts outside the HSA gene region and yields an 18 kb band if correct recombination occurred; Nco I: cuts outside the overlapping regions and yields bands of 8.0 and 9.3kb if correct recombination occurred; Nco I + Hind III: cuts at several positions outside the region of overlap, indicative of the presence of intact fragments; Hinc II: cuts in the overlapping regions, yielding several bands indicative of correct arrangement in these regions. In an initial experiment of 28 transgenic animals born, 22 had correctly recombined all three fragments. From 20 out of those 22 animals blood was collected and assayed for the presence of hSA protein using a radio immuno assay. 15 out of those 20 animals showed hSA expression at levels between .0.5 and 5 μg/mL. None of the animals that had no recombination or that were not transgenic showed any expression. Using RNA blots, only two (the two with the highest protein level) showed a band. We are currently performing blots on RNA that has been enriched for the presence of mRNA (i.e., poly(A)+ RNA) . Using reverse transcriptase to synthesize cDNA, followed by PCR, we have observed a perfect relationship between the presence of RNA and protein. However, in this experiment we could not determine the size(s) of the RNA. EXAMPLE 13 Alternate Construction of Transgenes Encoding hLF This example describes the construction of two hLF transgeneswhereinthe first contains approximately 16kb of αSl-casein 5' expression regulation sequence (pGPlhLF (16kb) also referred to as pl6,8HLF4) and the second contains approximately 7.9kbof αSl-casein 5' expression regulation sequence (pGPlhLF (8kb) also referred to as p8.8HLF4) . The overall strategy for these constructions is depicted in Fig. 9. A l.δkb EcoRI-Bglll fragment (fragment C in Fig. 9) was isolated from phage clone GP1. This fragment runs from position -100 of the transcription start site into the second exon of the αSl-casein gene. The Bglll site lies at the junction of the first entron and second exon of the αSl-casein gene. The 3' end containing the Bglll site was ligated to a synthetic Bglll-Clal linker and subcloned into the plasmid pUC19. The resulting plasmid is designated pEBS. Fragment B in Fig. 9 was isolated as an EcoRI fragment and cloned into the EcoRI site of pEBS. Fragment B includes sequences from position -7500 to position -100 of the transcription start site in the αSl-casein gene. The plasmid so formed is designated pEB3S-.and contains the combination of fragments B and C is the 8.9kb EcoRI- Clal fragment running from position -7500 to position +1400 of the transcription start site. The 8.9kb EcoRI- Clal fragment from pEB3, obtained by complete digestion with Clal and partial digestion with EcoRI was isolated and subcloned into EcoRI-Clal cut pKUN2 ( a derivative of pKUN; Gene (1986) 46_, 269-276 containing a Notl restriction site) to form pNE3BS. An 8.5kb Clal-EcoRI fragment (fragment A in Fig. 9) running from position -16000 to position -7500 of the transcription start site was isolated from phage GP1. It was thereafter subcloned into pUC19 to form pSE. Using synthetic oligonucleotide, a unique Notl site was introduced into the Clal site thereby destroying it. The resulting plasmid is designated pNE. The insert from pNE was isolated as a Notl-EcoRI fragment and together with the EcoRI-Clal insert from pNE3BS was ligated into the cloning vector pKUN2. The resulting plasmid pGPl (Δ2ex) contains 16kb of oSl- casein promoter plus the 5* end of the gene to the Bglll site at the border of the second exon. The final plasmid (16,8HLF4) containing the transgene was assembled using the Notl-Clal fragment from clone pGPI (Δ2ex) and the Xho-Notl fragment from clone pHLF 3' lOkb. The structure of this transgene is the same as previously described herein. As a minor modification to this plasmid the Sail site of this plasmid was removed by cutting with Sail and inserting a linker that contains a Notl site, but not a Sail site. Subsequently, a Sail site was introduced just downstream of the hLF sequence by cutting the Kpnl site at that position adding the following linker: 5'-CGTCGACAGTAC-3' (Seq. ID No.: 18) CATGGCAGCTGT-5• (Seq. ID No.: 19) In effect, the hLF sequence is now surrounded by two unique restriction sites (Clal and Sail) and can be replaced by any recombinant ANA sequence that has a Clal-site at the 5'- end and a Sail-site at the 3'- end. Another transgene was constructed that is identical to the foregoing except that it contains only about 8kb of 5' αSl-casein expression regulation sequence. It was constructed bytakingtheNotl-Clal fragment frompNE3BS and fusing it directly into Xho-Notl fragment from clone pHLF 3' lOkb. The resulting plasmid was designated pGPlhLF (7kb) (also referred to as p8.8HLF4). Plasmid 16,8hLF4 was modified to contain a hybrid splice signal ( Sl-casein-IgG) described in examples 3 and 5. The resulting plasmid was designated 16,8hLF3 and is identical to 16,8hLF4 except for the presence of a hybrid intron versus a "natural" casein intron in the 5'-UTR. The hLF signal sequence can also be used in all of the cDNA constructs disclosed herein instead of the casein signal sequence. This can be done in the following way: A synthetic oligo was made that contains the complete hLF signal sequence (see Fig. 2) plus a Clal restriction site at the 5'-end and an Eagl restriction site at the 3'-end. These restriction sites also border the casein- signal sequence in the other plasmids (e.g. , pl6,8hLF4) . A fragment containing the hLF-cDNA surrounded by Clal and Sail sites was cloned in pGEM7 (Stratagene, Inc.) containing a Clal and Sail site. The resulting plasmid was digested with Clal and Eagl and used as a vector to accommodate the Clal-Eagl fragment containing the hLF sequence. From the positive clones, the cDNA, with its own sequence, was excised as a Clal-Sall fragment and inserted in Clal-Sall digested pl6,8hLF4 to generate pl6,8hLF5. Similarly, this Cla-Sal fragment containing the hLF-cDNA plus hLF signal sequence can be inserted in any hLF cDNA vector. EXAMPLE 14 Production of Recombinant Human Lactoferin in the Milk of Transgenic Mice Transgenic mice were generated utilizing several of the transgenes identified in the examples herein. The transgenes used are identified in Table 3. In each case, the 5' and 3* expression regulation sequences were from the bovine αSl-casein gene, the RNA splice signal in the 5' untranslated region was either homologous from the αSl-casein gene or a hybrid casein-IgG intervening sequence. The recombinant DNA in each case was derived from cDNA clones. TABLE3 Construction of Transgene Cassette for Genomic R coφbinant DNA The plasmids described so far all contain regions derivedfromthebovine αSl-caseinuntranscribedregions (including intervening sequences) . When a genomic gene is to be expressed that already contains untranslated regions and intervening sequences permissive for high expression, it is preferable to use expression cassettes where the flanking regions of the αSl-casein gene are operably linked to the untranslated regions of the gene to be expressed. Such an expression cassette is p- 16kb,CS and was constructed as follows: plasmid pSl 3'5'hLF was used as a template in a PCR experiment. This plasmid contains 680 bp of promoter sequence of the αSl-casein gene as well as its first exon. the rest of this plasmid is not relevant for this experiment. The upstream primer was located just upstream of the insert in the plasmid moiety (just upstream of a Notl restriction site) . Its sequence is: 5'-CGA CGT TGT AAA ACG ACGG-3'. The downstream primer was located in exon 1. Its sequence matches the first 19 bp of the exon exactly and also has a non-hydridizing region of 17 bp containing a Clal and a Sail site. It has the following sequence: 5'-ATTGTCGACTTATCGATGGGTTGATGATCAAGGTGA-3' The amplified fragment was digested with Notl and Sail and ligated into pKUN2 (see Example 13) . The resulting plasmid (p-680CS) therefore harbors a proximal promoter fragment from -680 to + 19, plus two restriction sites just downstream of those 19 bp. This plasmid was digested with Notl (just upstream of - 680) and Nsil (at-280) and used as a vector to ligate to a fragment running from a Notl site (just upstream of -16kb) to Nsil (-280) isolated ^from pl6,8hLF4 (Example 13). This plasmid (p-16kb,CS) therefore harbors a promoter fragment from «-16,000 to +19. It can be used to insert genomic genes that carry their own UTR's and poly(A)-signal. After insertion of the genomic gene as a Clal-Sall fragment, the αSl-casein 3'- flanking region can be inserted as a Sail-fragment. EXAMPLE 16 Construction of Transgene for Production of Protein C The genomic sequence of Protein C has been published. Foster, et al. (1985) Proc. Natl. Acad. Sci. USA 82. 4673-4677. This sequence, however, does not include the first exon which was identified through the cDNA sequence published by Beckman, et al. (1985) Nucl. Acids Res. 13. 5233-5247. The first exon of Protein C is located at position -1499 to -1448 in the Foster sequence. The transgene for expressing and secreting Protein C into the milk of bovine species is shown in Fig. 10. This transgene was constructed as follows. A human genomic library in EMBL-3 (Clonotech) is probed with a sequence specific for protein C A purified phage DNA prep containing the complete Protein C gene is isolated. The phage is isolated from an JL. coli strain having the Dam phenotype, such a strain GM113. This results in cloned DNA which is not methylated and as such all Clal restriction sites can be cleaved. A Clal Nhel fragment running from positions +1333 to 11483 is isolated. This is designated fragment I. pGEM7 (Stratogene, Inc.) is digestedwith Sphl and Smal. The region in between is replaced by the corresponding region of plasmid pKUN (Gene (1986) 46., 269-276) . The resulting plasmid is designated pGEM7A and has the following restriction map in the relevant region: Hindlll . .«*...Clal Xbal Sail Spel Two primers are synthesized. Primer GP125 has the following sequence: 5' - CAA ATC GAT TGA ACT TGC AGT ATC TCC ACG AC - 3' Clal Primer GP 126 has the following sequence: 5' - GGG ATC GAT CAG ATT CTG TCC CCC AT - 3' Clal Primer GP125 has an overlap with exon 0 (position 654 to 675 of the Protein C gene) and introduces a Clal site in the 5' untranslated region. Exon O is the exon not identified by Foster, et a . Primer GP126 overlaps the region from 1344 to 1315 in the Protein C gene. This region contains a Clal site. The region between position 654 and 1344 is amplified using either human DNA or phage DNA as a template. The so amplified material is digested with Clal and cloned in vector pGEN7a to form pPCCC This vector is propagated in a dam negative strain such as GM113 and partially cut with Clal (only the plasmids that are cut once with Clal at position 1340 are of interest) and completely with Xbal. The Clal Nhel fragment (fragment 1) is cloned into this vector. The resultant plasmid is designated pPC Its structure is shown in Fig. 10. From this plasmid, the Protein C transgene is isolated as a Clal-Sall fragment and ligated into pl6Kb, CS (See Example 15) to generate a transgene capable of expressing Protein C in bovine milk, this plasmid is designated pl6 Kb,CS,PC The. transgene contained within plasmid p 16 Kb, CS, PC is excised with Notl and used to generate transgenic bovine species as previously described. Such transgenic animals are capable of producing protein C in their milk. Having described the preferred embodiments of the present invention, it will appear to those ordinarily skilled in the art that various modifications may be made to the disclosed embodiments, and that such modifications are intended to be within the scope of the present invention. All references disclosed herein are expressly incorporated by reference.

Claims: WHAT IS CLAIMED IS: 1. A transgene for producing a recombinant polypeptide in transgenic bovine species comprising at least one expression regulation DNA sequence functional in at least one cell-type of said bovine species operably linked to a recombinant DNA encoding a recombinant polypeptide, wherein said transgene is capable of directing the expression of said recombinant DNA sequence in at least said one cell-type of a bovine species containing said transgene to produce said recombinant polypeptide. 2. The transgene of Claim 1 wherein said expression regulation sequences comprise 5' and 3• expression regulation sequences from a serum albumin, said cell- type is liver cell, said recombinant polypeptide is human serum albumin and said transgene further comprises a secretory DNA sequence functional in said liver cells and operably linked to the recombinant DNA encoding said human serum albumin. 3. A transgene for producing a recombinant polypeptide in the milk of transgenic bovine species comprising at least one expression regulation DNA sequence functional in the mammary secretory cells of said bovine species, a secretory DNA sequence encoding a secretory signal sequence also functional in the mammary secretory cells of said bovine species and a recombinant DNA sequence encoding a recombinant polypeptide, said secretory DNA sequence being operably linked to said recombinant DNA sequence and to form a secretory-recombinant DNA sequence and said at least one expression regulation sequence being operably linked to said secretory-recombinant DNA sequence, wherein said transgene is capable of directing the expression of said secretory-recombinant DNA sequence inmammary secretory cells of bovine species containing said transgene to produce a form of recombinant polypeptide which when secreted from said mammary secretory cells produces recombinant polypeptide in he milk of said bovine species. 4. The transgene of Claim 1 or 3 further comprising a recombinant intervening sequence. 5. The transgene of Claim 4 wherein said recombinant intervening sequence is a hybrid intervening sequence. 6. The transgene of Claim 5 wherein said hybrid intervening sequence contains a permissive RNA splice signal. 7. The transgene of Claim 3 wherein said recombinant polypeptide is a homologous polypeptide from bovine species. 8. The transgene of Claim 7 wherein said homologous polypeptide is selected from the group consisting of caseins, lactoferrin, lysozyme, cholesterol hydrolase and serum albumin. 9. The transgene of Claim 3 wherein said recombinant polypeptide is a heterologous polypeptide. 10. The transgene of Claim 9 wherein said heterologous polypeptide is selected from the group consisting of humanmilk proteins, human serum proteins, and industrial enzymes. 11. The transgene of Claim 10 wherein said heterologous polypeptide is a human milk protein. 12. The transgene of Claim 11 wherein said humanmilk protein is selected from the group consisting of secretory immunoglobulins, lysozyme, lactoferrin, lactoglobulin, α-lactalbumin and bile salt-stimulated lipase. 13. The transgene of Claim 12 wherein said milk protein is lactoferrin. 14. The transgene of Claim 10 wherein said heterologous polypeptide is a human serum protein. 15. The transgene of Claim 14 wherein said human serum prpjtein is selected from the group consisting of albumin, immunoglobulin. Factor VIII, Factor IX and Protein C 16. The transgene of Claim 15 wherein said serum protein is albumin. 17. The transgene of Claim 10 wherein said heterologous polypeptide is an industrial enzyme selected from the group consisting of proteases, Upases, chitenases and ligninases. 18. The transgene of Claim 3 wherein said secretory DNA sequence is selected from the group consisting of DNA sequences encoding secretory signal sequences from human lactoferrin, human serum albumin, and secretory signal sequences from bovine αSl-casein, αS2-casein, β- casein, ic-casein, α-lactalbumin, 0-lactoglobulin, and serum albumin. 19. The transgene of Claim 18 wherein said secretory DNA sequence is the DNA sequence encoding the signal secretion sequence of bovine αSl casein. 20. The transgene of Claim 3 wherein said at least one . expression regulation sequence comprises 5' expression regulation DNA sequences, wherein said 5' expression regulation DNA sequence is operably linked to the 5' end of said secretory-recombinant DNA sequence. 21. The transgene of Claim 20 wherein said 5* expression regulation DNA sequence is selected from the group consisting of 5' expression regulation sequence from bovine genes encoding αSl-casein, αS2-casein, /8-casein, i-casein, α-lactalbumin, and β-lactoglobulin. 22. The transgene of Claim 21 wherein said 5' expression regulation DNA sequence is a proximal 5' expression regulation sequence comprising the promoter of bovine αSl-casein. 23. The transgene of Claim 22 wherein said 5' expression regulation DNA sequence further comprises a distal 5* expression regulation sequence comprising 5'-flanking DNA sequence from bovine αSl-casein. 24. The transgene of Claim 20 further comprising 3' expression regulation sequences operably linked to the 3' end'of said secretory-recombinant DNA sequence. 25. The transgene of Claim 24 wherein said 3' expression regulation sequence comprise 3' expression regulation sequence from bovine genes encoding αSl- casein, αS2-casein, j8-casein, k-casein, α-lactalbumin, and jS-lactoglobulin. 26. The transgene of Claim 25 wherein said 3' expression regulation DNA sequence comprises a 3' proximal expression regulation sequence from bovine αSl-casein. 27. The transgene of Claim 26 wherein said 3' expression regulation DNA sequence further comprises a 3' distal expression regulation sequence from bovine αSl-casein. 28. The transgene of Claim 27 wherein said distal 5' expression regulation DNA sequence comprises about a 30kb 5'-flanking region of bovine αSl-casein and said distal 3' expression regulation DNA sequence comprises about a 15kb 3'-flanking region of bovine αSl-casein. 29. A transgenic bovine species capable of producing a recombinant polypeptide in at least one cell type of said animal. 30. A transgenic bovine species capable of producing recombinant polypeptide in the milk of said trangenic species. 31. The transgenic bovine species of Claim 30 wherein saidrecombinantpolypeptide is ahomologouspolypeptide from bovine species. 32. The transgene bovine species of Claim 30 wherein said recombinant polypeptide is a heterologous polypeptide. 33. The transgenicbovine species of Claim 30 wherein said heterologous polypeptide is selected from the group consisting of humanmilk proteins, human serumproteins, and industrial enzymes. 34. The transgenic bovine species of Claim 33 wherein said heterologous polypeptide is a human milk protein. 35. The transgenic bovine species of Claim 34 wherein said human milk protein is selected from the group consisting of secretory immunoglobulins, lysozyme, lactoferrin, lactoglobulin, α-lactalbumin and bile salt- stimulated lipase. 36. Thetransgenic bovine species of Claim 35 wherein said milk protein is lactoferrin. 37. The transgenic bovine species of Claim 33 wherein said heterologous polypeptide is a human serum protein. 38. The transgenic bovine species of Claim 37 wherein said human serum protein is selected from the group consisting of albumin, immunoglobulin, Factor VIII, Factor IX and Protein C 39. The transgenic bovine species of Claim 38 wherein said serum protein is albumin. 40. The transgenic bovine species of Claim 33 wherein said heterologous polypeptide is an industrial enzyme selected from the group consisting of proteases, lipases, chitinases and ligninases. 41. Milk from transgenic bovine species containing a recombinant polypeptide. 42. The milk of Claim 41 wherein said recombinant polypeptide is a homologous polypeptide from bovine species. 43. The milk of Claim 41 wherein said recombinant polypeptide is a heterologous polypeptide. 44. The milk of Claim 43 wherein said heterologous polypeptide is selected from the group consisting of human milk proteins, human serum proteins, and industrial enzymes. 45. The milk of Claim 44 wherein said heterologous polypeptide is a human milk protein. 46. The milk of Claim 45 wherein said human milk protein is selected from the group consisting of secretory immunoglobulins, lysozyme, lactoferrin, lactoglobulin, α-lactalbumin and bile salt-stimulated lipase. 47. The milk of Claim 46 wherein said milk protein is lactoferrin. 48. The milk of Claim 43 wherein said heterologous polypeptide is a human serum protein. 49. The milk of Claim 48 wherein said human serum protein is selected from the group consisting of albumin, immunoglobulin. Factor VIII, Factor IX and Protein C 50. The milk of Claim 49 wherein said serum protein is albumin. 51. A food formulation comprising transgenic milk containing a recombinant polypeptide. 52. The food formulation of Claim 51 wherein said recombinant polypeptide is at least partially purified from said transgenic milk. 53. The food formulation of Claim 31 formulated with nutrients appropriate for infant formula. 54. A method for producing a transgenic bovine species capable of producing a recombinant polypeptide in the milk of said bovine species, said method comprising: introducing the transgene of Claim 1 into an embryonal target cell of a bovine species; transplanting the transgenic embryonal target cell formed thereby or the embryo obtained herefrom into a recipient female bovine parent; and identifying at least one female offspring which is capable of producing said recombinant polypeptide in the milk of said offspring. 55. A method for producing a transgenic non-human mammal having a desirable phenotype comprising: (a) methylating a transgene capable of conferring said phenotype when incorporated into the cells of said transgenic non-human animal; (b) introducing said methylated transgene into fertilized oocytes of said non-human mammal to permit integration of said transgene into the genomic DNA of said fertilized oocytes; (c) culturing the individual oocytes formed hereby to pre-implantation embryos thereby replicating the genome of each of said fertilized oocytes; (d) removing at least one cell from each of said pre- implantation embryos and lysing said at least one cell to release the DNA contained therein; (e) contacting said released DNA with a restriction endonuclease capable of cleaving said methylated transgene but incapable of cleaving the unmethylated form of said transgene formed after integration into and replication of said genomic DNA; and (f) detecting which of said cells from said pre- implantation embryos contain a transgene which is resistant to cleavage by said restriction endonuclease as an indication of which pre-implantation embryos have integrated said transgene. 56. The method of Claim 55 wherein said removal of at least one cell forms a first and second hemi-embryo for each of said pre-implementation embryos and each of said first hemi-embryos is lysed and analyzed according to steps (d) through (f) , said method further comprising; (g) cloning at least one of said second hemi- embryos; and (h) to form a multiplicity of transgenic embryos. 57. The method of Claim 56 further comprising transplanting more than one of said transgenic embryos into recipient female parents to produce a population containing at least two transgenic non-human animals having the same genotype. 58. The method of Claim 55 further comprising transplanting the remainder of said pre-implantation embryo containing a genomically integrated transgene into a recipient female parent and identifying at least one offspring having said phenotype. 59. The method of Claim 55 wherein said restriction endonuclease is DPNI and said transgene is methylated at N6 of the adenine of the sequence GATC contained within said transgene. 60. The method of Claim 59 wherein said detection utilizes a polymerase chain reaction using extension primers complementary to sequences upstream and downstream to said GATC sequence. 61. The method of Claim 59 wherein said non-human transgenic mammal is bovine species, said transgene encodes a recombinant polypeptide and said desired phenotype is the ability to produce said recombinant polypeptide in the milk of said bovine species. 62. The method of Claim 61 wherein said transgene is the transgene of Claim 3.

Inventors: DEBOER HERMAN A, HEYNEKER HERBERT L, LEE SANG HE, PLANTENBURG GERARD, STRIJKER REIN, DEBOER, HERMAN, A., HEYNEKER, HERBERT, L., LEE, SANG, HE, PLANTENBURG, GERARD, STRIJKER, REIN
Applicants: GENPHARM INT, GENPHARM INTERNATIONAL
Application year: 1990
Main classification: C07H21
IPC codes: A23C9, C07K14, C12N9, C12N15